2024

De Biase, N. et al. (2024) Associations of iron deficiency with cardiac function, congestion, exercise capacity and prognosis in heart failure. European Journal of Heart Failure, (Accepted for Publication)

Dieden, A. et al. (2024) Proteomic biomarkers and pathway analysis for progression to heart failure in three epidemiological representative cohorts. European Journal of Heart Failure, (doi: 10.1002/ejhf.3502) (PMID:39466935) (Early Online Publication)

Foley, P.W. et al. (2024) Effect of correcting iron deficiency on the risk of serious infection in heart failure insights from the IRONMAN trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3504) (PMID:39453738) (Early Online Publication)

Ho, F. et al. (2024) Maternal and pregnancy factors contributing to the association between area deprivation and infant mortality in England: a retrospective cohort study. Lancet Regional Health - Europe, (doi: 10.1016/j.lanepe.2024.101075) (In Press)

Varga, C. R., Cleland, J. G.F. , Abraham, W. T., Lip, G. Y.H., Leyva, F. and Hatamizadeh, P. (2024) Implantable cardioverter defibrillator and resynchronization therapy in patients with overt chronic kidney disease. Journal of the American College of Cardiology, 84(14), pp. 1342-1362. (doi: 10.1016/j.jacc.2024.05.081)

Cleland, J. G.F. (2024) Home-time is good, but feeling well is better: patient-journey and quality-home-time as endpoints in heart failure trials and registries. Circulation: Heart Failure, 17(10), e012263. (doi: 10.1161/CIRCHEARTFAILURE.124.012263) (PMID:39381873)

Keene, D. et al. (2024) Predictors of the efficacy of His bundle pacing in patients with a prolonged PR interval: A stratified analysis of the HOPE‐HF randomized controlled trial. European Journal of Heart Failure, 26(10), pp. 2261-2268. (doi: 10.1002/ejhf.3367) (PMID:39023285)

Lee, M. et al. (2024) Administration of ferric derisomaltose for iron deficiency and heart failure during hospital admission or at the clinic – insights from the IRONMAN trial. European Journal of Heart Failure, 26(10), pp. 2293-2295. (doi: 10.1002/ejhf.3394) (PMID:39078467)

Pellicori, P. , Cuthbert, J. J., Clark, A. L. and Cleland, J. G.F. (2024) Managing water and salt balance in heart failure: Is there anything else to consider other than diet and diuretics? European Journal of Heart Failure, 26(10), pp. 2140-2142. (doi: 10.1002/ejhf.3374) (PMID:39015063)

Yu, Y.-L. et al. (2024) Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial. Heart, 110(19), pp. 1180-1187. (doi: 10.1136/heartjnl-2023-323796) (PMID:38729636)

Cheng, L. et al. (2024) Long‐term follow‐up of the TRED ‐ HF trial: Implications for therapy in patients with dilated cardiomyopathy and heart failure remission. European Journal of Heart Failure, (doi: 10.1002/ejhf.3475) (PMID:39349993) (Early Online Publication)

Valentova, M. et al. (2024) Diabetes mellitus is associated with low exercise capacity and impaired peripheral vasodilation in patients with heart failure – a propensity score-matched stud. Diabetes Research and Clinical Practice, (Accepted for Publication)

Greene, S. J. et al. (2024) Cardiovascular and renal treatment in heart failure patients with hyperkalemia or high risk of hyperkalemia: rationale and design of the CARE-HK in HF registry. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2024.08.048) (PMID:39277029) (Early Online Publication)

Cuthbert, J. J., Cleland, J. G. F. , Pellicori, P. and Clark, A. L. (2024) Natriuresis guided diuresis in patients admitted to hospital with heart failure – barking up the wrong tree? Journal of Cardiac Failure, (Accepted for Publication)

Ponikowski, P. et al. (2024) Hospitalization of symptomatic patients with heart failure and moderate to severe functional mitral regurgitation treated with MitraClip: insights from RESHAPE-HF2. JACC: Heart Failure, (doi: 10.1016/j.jacc.2024.08.027) (PMID:39217574) (In Press)

Graham, F. J., Guha, K., Cleland, J. G. and Kalra, P. R. (2024) Treating iron deficiency in patients with heart failure: what, why, when, how, where and who. Heart, (doi: 10.1136/heartjnl-2022-322030) (PMID:39160066) (Early Online Publication)

Cleland, J. et al. (2024) The IRONMAN trial of intravenous iron for heart failure. Adjudication of hospitalizations and deaths. Journal of the American College of Cardiology, (Accepted for Publication)

Cao, T. H. et al. (2024) Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT‐CHF (European) study with the ASIAN‐HF registry. European Journal of Heart Failure, (doi: 10.1002/ejhf.3378) (PMID:39119882) (Early Online Publication)

Kazmi, S., Kambhampati, C., Rigby, A. S., Cleland, J. G.F. , Kazmi, K. S., Cuthbert, J., Pellicori, P. and Clark, A. L. (2024) Disease progression in chronic heart failure is linear: insights from multistate modelling. European Journal of Heart Failure, (doi: 10.1002/ejhf.3400) (PMID:39105488) (Early Online Publication)

Docherty, K. F. , McMurray, J. J.V. , Kalra, P., Cleland, J. G.F. , Lang, N. N. , Petrie, M. C. , Robertson, M. and Ford, I. (2024) Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction. ESC Heart Failure, 11(4), pp. 1875-1879. (doi: 10.1002/ehf2.14742) (PMID:38549192) (PMCID:PMC11287326)

Grobbee, D. E., Filippatos, G., Desai, N. R., Coats, A. J.S., Pinto, F., Rosano, G. M.C., Cleland, J. , Kammerer, J. and Ramirez de Arellano, A. (2024) Epidemiology and risk factors for hyperkalaemia in heart failure. ESC Heart Failure, 11(4), pp. 1821-1840. (doi: 10.1002/ehf2.14661) (PMID:38439165) (PMCID:PMC11287317)

Gustafsson, F. et al. (2024) 2-year outcomes of an atrial shunt device in HFpEF/HFmrEF: results from REDUCE LAP-HF II. JACC: Heart Failure, 12(8), pp. 1425-1438. (doi: 10.1016/j.jchf.2024.04.011) (PMID:38934964)

Sudesh, S. et al. (2024) Cardiac resynchronization therapy in ischemic versus non-ischemic cardiomyopathy: patient-level meta-analysis of seven randomized clinical trials. JACC: Heart Failure, (Accepted for Publication)

Bahar, J. et al. (2024) Outpatient treatment of decompensated heart failure: a systematic review and study level meta-analysis. ESC Heart Failure, (doi: 10.1002/ehf2.14841) (PMID:39013806) (Early Online Publication)

Rubiś, P. P., Dziewięcka, E., González, A. and Cleland, J. G.F. (2024) High variability in assays of blood markers of collagen turnover in cardiovascular disease: Implications for research and clinical practice. European Journal of Heart Failure, (doi: 10.1002/ejhf.3375) (PMID:38980205) (Early Online Publication)

Aguiar-Neves, I. et al. (2024) Health status and effects of spironolactone in people at high risk of heart failure: the Heart OMics in AGEing (HOMAGE) randomised trial. Clinical Cardiology, (Accepted for Publication)

Packer, M., Cleland, J. G.F. and Bauersachs, J. (2024) Great debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction. European Heart Journal, 45(25), pp. 2186-2196. (doi: 10.1093/eurheartj/ehae300) (PMID:38805680)

Anker, S. D. et al. (2024) Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials. European Journal of Heart Failure, 26(7), pp. 1608-1615. (doi: 10.1002/ejhf.3286) (PMID:38847420)

Cannata, A. et al. (2024) A nationwide, population-based study on specialized care for acute heart failure throughout the COVID-19 pandemic. European Journal of Heart Failure, 26(7), pp. 1574-1584. (doi: 10.1002/ejhf.3306) (PMID:38837310)

Lakhal-Littleton, S. and Cleland, J. G. F. (2024) Iron deficiency and supplementation in heart failure. Nature Reviews Cardiology, 21(7), pp. 463-486. (doi: 10.1038/s41569-024-00988-1) (PMID:38326440)

Conrad, N. et al. (2024) Temporal trends and patterns in cardiovascular disease incidence: a population-based study in 22 million individuals. British Medical Journal, 385, e078523. (doi: 10.1136/bmj-2023-078523) (PMID:38925788) (PMCID:PMC11203392)

Friday, J. M. et al. (2024) Loop diuretic utilisation with or without heart failure: impact on prognosis. European Heart Journal, (doi: 10.1093/eurheartj/ehae345) (PMID:38845446) (Early Online Publication)

Friedman, D. J. et al. (2024) Relationship between sex, body size, and cardiac resynchronization therapy benefit: a patient level meta-analysis of randomized controlled trials. Heart Rhythm, 21(6), pp. 845-854. (doi: 10.1016/j.hrthm.2024.01.058) (PMID:38360252)

Packer, M., Anker, S. D., Butler, J., Cleland, J. G.F. , Kalra, P. R., Mentz, R. J., Ponikowski, P. and Talha, K. M. (2024) Critical re‐evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure. European Journal of Heart Failure, 26(6), pp. 1298-1312. 38727791. (doi: 10.1002/ejhf.3237)

Kobayashi, M. et al. (2024) Proteomic profiles of left atrial volume and its influence on response to spironolactone: findings from the HOMAGE trial and STANISLAS cohort. European Journal of Heart Failure, 26(5), pp. 1231-1241. (doi: 10.1002/ejhf.3202) (PMID:38528728)

Ray, R. et al. (2024) The impact of ferric derisomaltose on cardiovascular and non-cardiovascular events in patients with anemia, iron deficiency and heart failure with reduced ejection fraction. Journal of Cardiac Failure, 30(5), pp. 682-690. (doi: 10.1016/j.cardfail.2023.10.006) (PMID:37926238) (PMCID:PMC11096866)

Cleland, J. G.F. et al. (2024) Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. European Heart Journal, 45(16), pp. 1410-1426. (doi: 10.1093/eurheartj/ehae086) (PMID:38446126) (PMCID:PMC11032711)

Fröhlich, A.-K. et al. (2024) Association of an impaired GH-IGF-I axis with cardiac wasting in patients with advanced cancer. Clinical Research in Cardiology, (doi: 10.1007/s00392-024-02400-x) (PMID:38587563) (Early Online Publication)

Cuthbert, J. J. et al. (2024) Medicines optimization prior to discharge in patients admitted to hospital with heart failure. ESC Heart Failure, 11(2), pp. 950-961. (doi: 10.1002/ehf2.14638) (PMID:38229241) (PMCID:PMC10966249)

Fudim, M. et al. (2024) Comorbidities and clinical response to cardiac resynchronization therapy: patient-level meta-analysis from eight clinical trials. European Journal of Heart Failure, 26(4), pp. 1039-1046. (doi: 10.1002/ejhf.3029) (PMID:37671601)

Monzo, L. et al. (2024) High risk of stroke in patients with worsening heart failure, reduced ejection fraction, coronary heart disease and sinus rhythm: risk prediction score analysis from the COMMANDER-HF trial. Journal of Cardiac Failure, 30(4), pp. 618-623. (doi: 10.1016/j.cardfail.2023.11.020) (PMID:38122924)

Cleland, J. G.F. (2024) Nature and magnitude of the benefits of dapagliflozin and empagliflozin for heart failure. Circulation, 149(11), pp. 839-842. (doi: 10.1161/circulationaha.123.068089) (PMID:38466791)

Cleland, J. G.F. , Pellicori, P. and Lakhal-Littleton, S. (2024) Low serum ferritin might predict incident heart failure but why and is it clinically useful? JACC: Heart Failure, 12(3), pp. 549-551. (doi: 10.1016/j.jchf.2023.12.012) (PMID:38340135)

AI Abel, A., Samuel, N. A., Cuthbert, J. J., Brown, O. I., Pellicori, P. , Kazmi, S., Cleland, J. G.F. , Johnson, M. J. and Clark, A. L. (2024) Hospital admissions in the last year of life of patients with heart failure. European Heart Journal: Quality of Care and Clinical Outcomes, 10(2), pp. 168-175. (doi: 10.1093/ehjqcco/qcad047) (PMID:37553153)

Pellicori, P. , Felker, G. M. and Cleland, J. G.F. (2024) Reply to ‘Vasodilators in congestive heart failure: The perfect weapon aiming just off the target?’. European Journal of Heart Failure, 26(2), p. 528. (doi: 10.1002/ejhf.3159) (PMID:38379019)

Pellicori, P. and Cleland, J. G.F. (2024) Atrial myopathy and heart failure with preserved ejection fraction: When a label does more harm than good? European Journal of Heart Failure, 26(2), pp. 299-301. (doi: 10.1002/ejhf.3148) (PMID:38282265)

Santos-Ferreira, D. et al. (2024) Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial. ESC Heart Failure, 11(1), pp. 209-218. (doi: 10.1002/ehf2.14465) (PMID:37939716) (PMCID:PMC10804163)

Pellicori, P. , Hunter, D., Khin, H. H. E. and Cleland, J. G.F. (2024) How to diagnose and treat venous congestion in heart failure. European Heart Journal, (doi: 10.1093/eurheartj/ehad883) (PMID:38195064) (Early Online Publication)

Cleland, J. G. F. (2024) Defining iron deficiency in patients with heart failure. Nature Reviews Cardiology, 21(1), pp. 1-2. (doi: 10.1038/s41569-023-00951-6) (PMID:37875635)

Pellicori, P. et al. (2024) Impact of vasodilators on diuretic response in patients with congestive heart failure: a mechanistic trial of cimlanod (BMS‐986231). European Journal of Heart Failure, 26(1), pp. 142-151. (doi: 10.1002/ejhf.3077) (PMID:37990754)

Zeitler, E. P. et al. (2024) Benefit of cardiac resynchronization therapy among older patients: A patient-level meta-analysis. American Heart Journal, 267, pp. 81-90. (doi: 10.1016/j.ahj.2023.11.002) (PMID:37984672)

2023

Welsh, P. et al. (2023) Multiple cardiac biomarkers to improve prediction of cardiovascular events: findings from the Generation Scotland Scottish Family Health Study. Clinical Chemistry, 70(2), pp. 403-413. (doi: 10.1093/clinchem/hvad205) (PMID:38069915)

Flett, A., Cebula, A., Nicholas, Z., Adam, R., Ewings, S., Prasad, S., Cleland, J. G.F. , Eminton, Z. and Curzen, N. (2023) Rationale and study protocol for the BRITISH randomised trial (using cardiovascular magnetic resonance identified scar as the Benchmark Risk Indication Tool for Implantable cardioverter defibrillators in patients with non-ischaemic cardiomyopathy and severe systolic heart failure). American Heart Journal, 266, pp. 149-158. (doi: 10.1016/j.ahj.2023.09.008) (PMID:37777041)

Purcell, C. , Purvis, A., Cleland, J. G.F. , Cowie, A., Dalal, H. M., Ibbotson, T. , Murphy, C. and Taylor, R. S. (2023) Home-based cardiac rehabilitation for people with heart failure and their caregivers: a mixed-methods analysis of the roll out an evidence-based programme in Scotland (SCOT:REACH-HF study). European Journal of Cardiovascular Nursing, 22(8), pp. 804-813. (doi: 10.1093/eurjcn/zvad004) (PMID:36617216)

McDonagh, T. A. et al. (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 44(37), pp. 3627-3639. (doi: 10.1093/eurheartj/ehad195) (PMID:37622666)

Bozkurt, B. et al. (2023) Mortality, outcomes, costs, and use of medicines following a first heart failure hospitalization: EVOLUTION HF. JACC: Heart Failure, 11(10), pp. 1320-1332. (doi: 10.1016/j.jchf.2023.04.017) (PMID:37354145)

Cuthbert, J. J. and Cleland, J. G.F. (2023) Should we resurrect acetazolamide as a diuretic for congestion due to heart failure? Cardiovascular Research, 119(14), e149-e151. (doi: 10.1093/cvr/cvad148) (PMID:37850512)

Graham, F. J., Pellicori, P. , Masini, G., Cuthbert, J. J., Clark, A. L. and Cleland, J. G.F. (2023) Influence of serum transferrin concentration on diagnostic criteria for iron deficiency in chronic heart failure. ESC Heart Failure, 10(5), pp. 2826-2836. (doi: 10.1002/ehf2.14438) (PMID:37400990) (PMCID:PMC10567655)

Wei, L. , Phillippo, D. M., Shah, A., Cleland, J. G.F. , Lewsey, J. and McAllister, D. A. (2023) Transportability of two heart failure trials to a disease registry using individual patient data. Journal of Clinical Epidemiology, 162, pp. 160-168. (doi: 10.1016/j.jclinepi.2023.08.019) (PMID:37659583)

Graham, F. J., Friday, J. , Pellicori, P. , Greenlaw, N. and Cleland, J. G.F. (2023) Assessment of haemoglobin and serum markers of iron deficiency in people with cardiovascular disease. Heart, 109(17), pp. 1294-1301. (doi: 10.1136/heartjnl-2022-322145) (PMID:37130747)

Tromp, J. et al. (2023) Global variations according to sex in patients hospitalized for heart failure in the REPORT-HF registry. JACC: Heart Failure, 11(9), pp. 1262-1271. (doi: 10.1016/j.jchf.2023.06.028) (PMID:37678961)

de Koning, M.-S. L.Y. et al. (2023) Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure. Clinical Research in Cardiology, 112(8), pp. 1056-1066. (doi: 10.1007/s00392-023-02171-x) (PMID:36997667) (PMCID:PMC10062262)

Iaconelli, A., Cuthbert, J., Kazmi, S., Maffia, P. , Clark, A. L., Cleland, J. G.F. and Pellicori, P. (2023) Inferior vena cava diameter is associated with prognosis in patients with chronic heart failure independent of tricuspid regurgitation velocity. Clinical Research in Cardiology, 112(8), pp. 1077-1086. (doi: 10.1007/s00392-023-02178-4) (PMID:36894788) (PMCID:PMC10359207)

Iaconelli, A., Pellicori, P. , Caiazzo, E., Rezig, A. O. M. , Bruzzese, D., Maffia, P. and Cleland, J. G. F. (2023) Implanted haemodynamic telemonitoring devices to guide management of heart failure: a review and meta-analysis of randomised trials. Clinical Research in Cardiology, 112(8), pp. 1007-1019. (doi: 10.1007/s00392-022-02104-0) (PMID:36241896) (PMCID:PMC9568893)

Jones, R. E. et al. (2023) Assessment of left ventricular tissue mitochondrial bioenergetics in patients with stable coronary artery disease. Nature Cardiovascular Research, 2(8), pp. 733-745. (doi: 10.1038/s44161-023-00312-z)

Kobayashi, M. et al. (2023) A machine learning derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: findings from the HOMAGE trial. European Journal of Heart Failure, 25(8), pp. 1284-1289. (doi: 10.1002/ejhf.2859) (PMID:37062878)

Iaconelli, A. et al. (2023) Coronary revascularization for heart failure with coronary artery disease: a systematic review and meta-analysis of randomized trials. European Journal of Heart Failure, 25(7), pp. 1170-1175. (doi: 10.1002/ejhf.2911) (PMID:37211964)

Pugliese, N. R. et al. (2023) The incremental value of multi-organ assessment of congestion using ultrasound in outpatients with heart failure. European Heart Journal: Cardiovascular Imaging, 24(7), pp. 961-971. (doi: 10.1093/ehjci/jeac254) (PMID:36595324)

Cleland, J. G.F. , Pellicori, P. and Graham, F. J. (2023) Redefining both iron deficiency and anaemia in cardiovascular disease. European Heart Journal, 44(22), pp. 1992-1994. (doi: 10.1093/eurheartj/ehad154) (PMID:36879446)

Butcher, C.J.T. et al. (2023) Variation in optimal hemodynamic atrio-ventricular delay of biventricular pacing with different endocardial left ventricular lead locations using precision hemodynamics. Journal of Cardiovascular Electrophysiology, 34(6), pp. 1431-1440. (doi: 10.1111/jce.15862) (PMID:36786511)

Farmakis, D. et al. (2023) Impact of left ventricular ejection fraction phenotypes on healthcare-resource utilization in hospitalized heart failure: a secondary analysis of REPORT-HF. European Journal of Heart Failure, 25(6), pp. 818-828. (doi: 10.1002/ejhf.2833) (PMID:36974770)

Graham, F., Iaconelli, A., Sonecki, P., Campbell, R. T., Hunter, D., Cleland, J. G.F. and Pellicori, P. (2023) Defining heart failure based on imaging the heart and beyond. Cardiac Failure Review, 9, e11. (doi: 10.15420/cfr.2022.29) (PMID:37427007) (PMCID:PMC10326661)

Markousis-Mavrogenis, G. et al. (2023) Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure. Cardiovascular Research, 119(8), pp. 1690-1705. (doi: 10.1093/cvr/cvad042) (PMID:36883593) (PMCID:PMC10325696)

Metra, M. et al. (2023) Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure, 25(6), pp. 776-791. (doi: 10.1002/ejhf.2874) (PMID:37208936)

Girerd, N. et al. (2023) Protein biomarkers of new-onset heart failure: insights from the Heart Omics and Ageing cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study. Circulation: Heart Failure, 16(5), pp. 426-441. (doi: 10.1161/CIRCHEARTFAILURE.122.009694) (PMID:37192292) (PMCID:PMC10179982)

Ferreira, J. P. et al. (2023) Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: pooled analysis of three randomized trials. International Journal of Cardiology, 377, pp. 86-88. (doi: 10.1016/j.ijcard.2023.01.088) (PMID:36738846)

Cuthbert, J.J., Pellicori, P. , Rigby, A.S., Abel, A.A.I., Kalvickbacka-Bennet, A., Shah, P., Kearsley, J.W., Kazmi, S., Cleland, J.G.F. and Clark, A.L. (2023) Are non-invasive estimations of plasma volume an accurate measure of congestion in patients with chronic heart failure? European Heart Journal: Quality of Care and Clinical Outcomes, 9(3), pp. 281-292. (doi: 10.1093/ehjqcco/qcac035) (PMID:35723241)

Graham, F. J., Pellicori, P. , Kalra, P. R., Ford, I. , Bruzzese, D. and Cleland, J. G.F. (2023) Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis. European Journal of Heart Failure, 25(4), pp. 528-537. (doi: 10.1002/ejhf.2810) (PMID:36823953)

Leo, V. C., Kazmi, S., Brownrigg, J., Araghi, M., Sarna, H. S., Pellicori, P. , Cuthbert, J., Cleland, J. G.F. and Clark, A. L. (2023) Estimating nuclear scanning capacity requirements for patients with suspected cardiac transthyretin amyloidosis. ESC Heart Failure, 10(2), pp. 1492-1496. (doi: 10.1002/ehf2.14315) (PMID:36811158) (PMCID:PMC10053180)

Ferreira, J. P. et al. (2023) Effect of spironolactone on QRS duration in patients at risk for heart failure (from the HOMAGE trial). American Journal of Cardiology, 191, pp. 39-42. (doi: 10.1016/j.amjcard.2022.12.016)

Friedman, D. J. et al. (2023) Cardiac resynchronization therapy improves outcomes in patients with intraventricular conduction delay but not right bundle branch block: a patient-level meta-analysis of randomized controlled trials. Circulation, 147(10), pp. 812-823. (doi: 10.1161/CIRCULATIONAHA.122.062124) (PMID:36700426)

Nuzzi, V. et al. (2023) Diuretic dose trajectories in dilated cardiomyopathy: prognostic implications. Clinical Research in Cardiology, 112(3), pp. 419-430. (doi: 10.1007/s00392-022-02126-8) (PMID:36385396) (PMCID:PMC9998319)

Packer, M. and Cleland, J. G.F. (2023) Combining iron supplements with SGLT2 inhibitor-stimulated erythropoiesis in heart failure: should we be worried about thromboembolic events? Journal of Cardiac Failure, 29(3), pp. 403-406. (doi: 10.1016/j.cardfail.2022.12.007) (PMID:36563739)

Boorsma, E. M. et al. (2023) Albuminuria as a marker of systemic congestion in patients with heart failure. European Heart Journal, 44(5), pp. 368-380. (doi: 10.1093/eurheartj/ehac528) (PMID:36148485) (PMCID:PMC9890244)

Docherty, K. F. et al. (2023) Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B ‐type natriuretic peptide level: insights from the GALACTIC‐HF trial. European Journal of Heart Failure, 25(2), pp. 248-259. (doi: 10.1002/ejhf.2763) (PMID:36597719)

Whinnett, Z. I. et al. (2023) Effects of haemodynamically atrio‐ventricular optimized His‐pacing on heart failure symptoms and exercise capacity: the His Optimized Pacing Evaluated for Heart Failure (HOPE‐HF) randomised, double‐blind, cross‐over trial. European Journal of Heart Failure, 25(2), pp. 274-283. (doi: 10.1002/ejhf.2736) (PMID:36404397)

Sykes, R. et al. (2023) Rationale and design of the effect of mineralocorticoid receptor antagonist therapy in patients with acute myocardial infarction or injury and non-obstructive coronary arteries: A registry-based, stratified-medicine, randomised, controlled trial. British Society of Cardiovascular Magnetic Resonance (BSCMR) 17th Annual Congress, Liverpool, UK, 11-12 Oct 2022. (doi: 10.1136/heartjnl-2022-BSCMR.26)

Savarese, G., von Haehling, S., Butler, J., Cleland, J. G.F. , Ponikowski, P. and Anker, S. D. (2023) Iron deficiency and cardiovascular disease. European Heart Journal, 44(1), pp. 14-27. (doi: 10.1093/eurheartj/ehac569) (PMID:36282723) (PMCID:PMC9805408)

Ferreira, J. P. et al. (2023) Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials. European Journal of Heart Failure, 25(1), pp. 108-113. (doi: 10.1002/ejhf.2726) (PMID:36303266)

Manla, Y., Kuan, W., Clark, A. L., Cleland, J. G. F. and Pellicori, P. (2023) Ketone bodies in acute heart failure: fuel for thought. Journal of Cardiac Failure, 29(1), pp. 42-44. (doi: 10.1016/j.cardfail.2022.11.002) (PMID:36402423)

Ouwerkerk, W. et al. (2023) Association of time‐to‐IV ‐furosemide with mortality in acute heart failure: data from REPORT‐HF. European Journal of Heart Failure, 25(1), pp. 43-51. (doi: 10.1002/ejhf.2708) (PMID:36196060)

2022

Kalra, P. R. et al. (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 400(10369), pp. 2199-2209. (doi: 10.1016/S0140-6736(22)02083-9) (PMID:36347265)

Bhandari, S., Mehta, S., Khwaja, A., Cleland, J. G.F. , Ives, N., Brettell, E., Chadburn, M. and Cockwell, P. (2022) Renin-angiotensin system inhibition in advanced chronic kidney disease. New England Journal of Medicine, 387(22), pp. 2021-2032. (doi: 10.1056/NEJMoa2210639) (PMID:36326117)

Bracun, V. et al. (2022) Insulin‐like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence. ESC Heart Failure, 9(6), pp. 4167-4176. (doi: 10.1002/ehf2.14120) (PMID:36088651) (PMCID:PMC9773704)

Kalra, P. R. et al. (2022) Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart, 108(24), pp. 1979-1985. (doi: 10.1136/heartjnl-2022-321304) (PMID:35948408) (PMCID:PMC9726969)

Monzo, L. et al. (2022) Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial. ESC Heart Failure, 9(6), pp. 4352-4357. (doi: 10.1002/ehf2.14086) (PMID:36065795) (PMCID:PMC9773649)

Pugliese, N. R., Pellicori, P. , Filidei, F., De Biase, N., Maffia, P. , Guzik, T. J., Masi, S., Taddei, S. and Cleland, J. G.F. (2022) Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. Cardiovascular Research, 118(18), pp. 3536-3555. (doi: 10.1093/cvr/cvac133) (PMID:36004819) (PMCID:PMC9897694)

Butler, J. et al. (2022) Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. European Heart Journal, 43(41), pp. 4362-4373. (doi: 10.1093/eurheartj/ehac401) (PMID:35900838) (PMCID:PMC9622299)

Inciardi, R. M. et al. (2022) Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure. European Journal of Heart Failure, 24(11), pp. 2131-2139. (doi: 10.1002/ejhf.2593) (PMID:35748048)

Pellicori, P. , Kalra, P. R., Clark, A. L., Friday, J. and Cleland, J. G. F. (2022) Chronic kidney disease (CKD) and CKD-ism in heart failure – what a mess! European Journal of Heart Failure, 24(11), pp. 2196-2198. (doi: 10.1002/ejhf.2696) (PMID:36130835)

Salah, H. M., Goldberg, L. R., Molinger, J., Felker, G. M., Applefeld, W., Rassaf, T., Tedford, R. J., Mirro, M., Cleland, J. G.F. and Fudim, M. (2022) Diaphragmatic function in cardiovascular disease: JACC review topic of the week. Journal of the American College of Cardiology, 80(17), pp. 1647-1659. (doi: 10.1016/j.jacc.2022.08.760) (PMID:36265961)

Lota, A. S. et al. (2022) Genetic architecture of acute myocarditis and the overlap with inherited cardiomyopathy. Circulation, 146(15), pp. 1123-1134. (doi: 10.1161/CIRCULATIONAHA.121.058457) (PMID:36154167) (PMCID:PMC9555763)

Baumhove, L. et al. (2022) Heart failure with normal LVEF in BIOSTAT-CHF. International Journal of Cardiology, 364, pp. 85-90. (doi: 10.1016/j.ijcard.2022.05.054) (PMID:35649488)

Kazmi, S., Kambhampati, C., Cleland, J. G.F. , Cuthbert, J., Kazmi, K. S., Pellicori, P. , Rigby, A. S. and Clark, A. L. (2022) Dynamic risk stratification using Markov chain modelling in patients with chronic heart failure. ESC Heart Failure, 9(5), pp. 3009-3018. (doi: 10.1002/ehf2.14028) (PMID:35736536) (PMCID:PMC9715820)

Kobayashi, M. et al. (2022) The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial. European Journal of Heart Failure, 24(9), pp. 1559-1568. (doi: 10.1002/ejhf.2579) (PMID:35703355)

Ravera, A. et al. (2022) Distinct pathophysiological pathways in women and men with heart failure. European Journal of Heart Failure, 24(9), pp. 1532-1544. (doi: 10.1002/ejhf.2534) (PMID:35596674)

Deo, S. V. et al. (2022) Revascularization in ischemic heart failure with preserved ejection fraction: a nationwide cohort study. European Journal of Heart Failure, 24(8), pp. 1427-1438. (doi: 10.1002/ejhf.2446) (PMID:35119162)

Jorbendaze, A. et al. (2022) Synchronized diaphragmatic stimulation for heart failure using the VisONE system: a first‐in‐patient study. ESC Heart Failure, 9(4), pp. 2207-2214. (doi: 10.1002/ehf2.13984) (PMID:35619238) (PMCID:PMC9288796)

Pagnesi, M. et al. (2022) Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. Clinical Research in Cardiology, 111(8), pp. 912-923. (doi: 10.1007/s00392-022-01991-7) (PMID:35294624)

Rossignol, P. et al. (2022) Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease. Pharmacological Research, 182, 106277. (doi: 10.1016/j.phrs.2022.106277) (PMID:35662631)

Savarese, G. et al. (2022) Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction. ESC Heart Failure, 9(4), pp. 2107-2118. (doi: 10.1002/ehf2.13917) (PMID:35388650) (PMCID:PMC9288797)

Cowie, M. and Cleland, J. G.F. (2022) The COVID-19 pandemic and heart failure: lessons from GUIDE-HF. European Heart Journal, 43(27), pp. 2619-2621. (doi: 10.1093/eurheartj/ehac226) (PMID:35511076) (PMCID:PMC9279113)

Lewinter, C., Nielsen, T. H., Edfors, L. R., Linde, C., Bland, J. M., LeWinter, M., Cleland, J. G.F. , Køber, L., Braunschweig, F. and Mansson-Broberg, A. (2022) A systematic review and meta-analysis of beta-blockers and inhibitors of the renin-angiotensin system for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. European Heart Journal, 43(27), pp. 2562-2569. (doi: 10.1093/eurheartj/ehab843) (PMID:34951629)

Cester, L., Starshynov, I. , Jones, Y., Pellicori, P. , Cleland, J. G.F. and Faccio, D. (2022) Remote laser-speckle sensing of heart sounds for health assessment and biometric identification. Biomedical Optics Express, 13(7), pp. 3743-3750. (doi: 10.1364/BOE.451416) (PMID:35991923) (PMCID:PMC9352283)

Cohen, D. J., Magnuson, E., Stone, G. W. and Cleland, J. G.F. (2022) Response to: correspondence on 'Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation does need confirmation' by Armoiry and Connock. Heart, 108(13), 1072. (doi: 10.1136/heartjnl-2022-321180) (PMID:35534052)

Cooper, T. J. et al. (2022) Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomised placebo‐controlled multicentre trial. European Journal of Heart Failure, 24(7), pp. 1239-1248. (doi: 10.1002/ejhf.2527) (PMID:35596935)

Rao, S., Li, Y., Ramakrishnan, R., Hassaine, A., Canoy, D., Cleland, J. G. , Lukasiewicz, T., Salimi-Khorshidi, G. and Rahimi, K. (2022) An explainable transformer-based deep learning model for the prediction of incident heart failure. IEEE Journal of Biomedical and Health Informatics, 26(7), pp. 3362-3372. (doi: 10.1109/JBHI.2022.3148820) (PMID:35130176)

Santema, B. T. et al. (2022) Pathophysiological pathways in patients with heart failure and atrial fibrillation. Cardiovascular Research, 118(11), pp. 2478-2487. (doi: 10.1093/cvr/cvab331) (PMID:34687289) (PMCID:PMC9400416)

Aktaa, S. et al. (2022) Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart). European Heart Journal, 43(23), pp. 2185-2195. (doi: 10.1093/eurheartj/ehac151) (PMID:35443059)

Tromp, J. et al. (2022) Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. European Heart Journal, 43(23), pp. 2224-2234. (doi: 10.1093/eurheartj/ehac103) (PMID:35393622)

Tayal, U. et al. (2022) Precision phenotyping of dilated cardiomyopathy using multidimensional data. Journal of the American College of Cardiology, 79(22), pp. 2219-2232. (doi: 10.1016/j.jacc.2022.03.375) (PMID:35654493) (PMCID:PMC9168440)

Bomer, N., Pavez-Giani, M. G., Grote Beverborg, N., Cleland, J. G.F. , van Veldhuisen, D. J. and van der Meer, P. (2022) Micronutrient deficiencies in heart failure: mitochondrial dysfunction as a common pathophysiological mechanism? Journal of Internal Medicine, 291(6), pp. 713-731. (doi: 10.1111/joim.13456) (PMID:35137472) (PMCID:PMC9303299)

Boyalla, V. et al. (2022) Biomarkers as predictors of recurrence of atrial fibrillation post ablation: an updated and expanded systematic review and meta-analysis. Clinical Research in Cardiology, 111(6), pp. 680-691. (doi: 10.1007/s00392-021-01978-w) (PMID:34999932) (PMCID:PMC9151522)

Cleland, J. G.F. et al. (2022) The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual-patient-data meta-analysis of COMPANION and CARE-HF. European Journal of Heart Failure, 24(6), pp. 1080-1090. (doi: 10.1002/ejhf.2524) (PMID:35490339) (PMCID:PMC9543287)

Goldberg, L. R., Jorbenadze, A., Shaburishvilli, T., Mirro, M. J., Fudim, M., Zuber, M., Stämpfli, S. F., Tanner, F. C., Erne, P. and Cleland, J. G. (2022) Synchronized diaphragmatic stimulation: a case report of a novel extra-cardiac intervention for chronic heart failure. ESC Heart Failure, 9(3), pp. 1677-1681. (doi: 10.1002/ehf2.13882) (PMID:35297198) (PMCID:PMC9065831)

Halliday, B. P. et al. (2022) Changes in clinical and imaging variables during withdrawal of heart failure therapy in recovered dilated cardiomyopathy. ESC Heart Failure, 9(3), pp. 1616-1624. (doi: 10.1002/ehf2.13872) (PMID:35257498) (PMCID:PMC9065828)

Ho, F. K. et al. (2022) Association of gamma-glutamyltransferase levels with total mortality, liver-related, and cardiovascular outcomes: a prospective cohort study in the UK Biobank. EClinicalMedicine, 48, 101435. (doi: 10.1016/j.eclinm.2022.101435) (PMID:35706481) (PMCID:PMC9112033)

Israr, M. Z. et al. (2022) Surrogate markers of gut dysfunction are related to heart failure severity and outcome - from the BIOSTAT-CHF consortium. American Heart Journal, 248, pp. 108-119. (doi: 10.1016/j.ahj.2022.03.002) (PMID:35278373)

McNaughton, C. D. et al. (2022) Quality of life assessed six months after hospitalisation for acute heart failure: an analysis from REPORT‐HF (International Registry to assess mEdical Practice with lOngitudinal obseRvation for Treatment of Heart Failure). European Journal of Heart Failure, 24(6), pp. 1020-1029. (doi: 10.1002/ejhf.2508) (PMID:35429091)

Nath, M. et al. (2022) Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure. European Journal of Heart Failure, 24(6), pp. 1009-1019. (doi: 10.1002/ejhf.2540) (PMID:35570197)

Pellicori, P. and Cleland, J. G. F. (2022) Heart failure: age is no excuse for complacency. European Journal of Heart Failure, 24(6), pp. 1063-1065. (doi: 10.1002/ejhf.2517) (PMID:35481861)

Rastogi, T. et al. (2022) Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from HOMAGE and the UK Biobank. European Journal of Heart Failure, 24(6), pp. 976-984. (doi: 10.1002/ejhf.2495) (PMID:35365899) (PMCID:PMC9542039)

Streng, K. W. et al. (2022) Clinical implications of low estimated protein intake in patients with heart failure. Journal of Cachexia, Sarcopenia and Muscle, 13(3), pp. 1762-1770. (doi: 10.1002/jcsm.12973) (PMID:35426256) (PMCID:PMC9178387)

Borlaug, B. A. et al. (2022) Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure. Circulation, 145(21), pp. 1592-1604. (doi: 10.1161/CIRCULATIONAHA.122.059486) (PMID:35354306) (PMCID:PMC9133195)

Girerd, N. et al. (2022) Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction. Scientific Reports, 12, 8574. (doi: 10.1038/s41598-022-12385-0) (PMID:35595781) (PMCID:PMC9123183)

Fairbairn, T. et al. (2022) Effect of transcatheter aortic valve implantation vs surgical aortic valve replacement on all-cause mortality in patients with aortic stenosis. JAMA: Journal of the American Medical Association, 327(19), pp. 1875-1887. (doi: 10.1001/jama.2022.5776) (PMID:35579641)

Cleland, J. G.F. (2022) Maintaining public trust in medical advice—could less be more? JAMA Network Open, 5(5), e2211113. (doi: 10.1001/jamanetworkopen.2022.11113) (PMID:35536584)

Cohen, D. J. et al. (2022) Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation. Heart, 108(9), pp. 717-724. (doi: 10.1136/heartjnl-2021-320005) (PMID:35078867) (PMCID:PMC8995818)

Ferreira, J. P. et al. (2022) Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial. European Journal of Heart Failure, 24(5), pp. 771-778. (doi: 10.1002/ejhf.2455) (PMID:35199421)

Graham, F. J., Masini, G., Pellicori, P. , Cleland, J. G.F. , Greenlaw, N. , Friday, J. , Kazmi, S. and Clark, A. L. (2022) Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure. European Journal of Heart Failure, 24(5), pp. 807-817. (doi: 10.1002/ejhf.2251) (PMID:34050582)

Halliday, B. P. and Cleland, J. G. F. (2022) Maintaining success for patients with dilated cardiomyopathy and remission of heart failure. JACC: Basic to Translational Science, 7(5), pp. 500-503. (doi: 10.1016/j.jacbts.2022.03.008) (PMID:35663636) (PMCID:PMC9156436)

Markousis-Mavrogenis, G. et al. (2022) Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF. Cardiovascular Research, 118(8), pp. 1964-1977. (doi: 10.1093/cvr/cvab235) (PMID:34264317)

Pellicori, P. , McConnachie, A. , Carlin, C., Wales, A. and Cleland, J. G.F. (2022) Predicting mortality after hospitalisation for COPD using electronic health records. Pharmacological Research, 179, 106199. (doi: 10.1016/j.phrs.2022.106199) (PMID:35381341)

Verdonschot, J. A.J. et al. (2022) The effect of spironolactone in patients with obesity at risk for heart failure: proteomic insights from the HOMAGE trial. Journal of Cardiac Failure, 28(5), pp. 778-786. (doi: 10.1016/j.cardfail.2021.12.005) (PMID:34933097)

Cleland, J. G.F. , Butler, J., Januzzi, J. L., Pellicori, P. and McDonagh, T. (2022) Only people with increased plasma concentrations of natriuretic peptides should be included in outcome trials of diabetes, cardiovascular and kidney disease: implications for clinical practice. European Journal of Heart Failure, 24(4), pp. 678-680. (doi: 10.1002/ejhf.2488) (PMID:35297132)

Täger, T., Frankenstein, L., Atar, D., Agewall, S., Frey, N., Grundtvig, M., Clark, A. L., Cleland, J. G.F. and Fröhlich, H. (2022) Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. Clinical Research in Cardiology, 111(4), pp. 428-439. (doi: 10.1007/s00392-021-01913-z) (PMID:34498169)

Tayal, U. et al. (2022) Moderate excess alcohol consumption and adverse cardiac remodelling in dilated cardiomyopathy. Heart, 108(8), pp. 619-625. (doi: 10.1136/heartjnl-2021-319418) (PMID:34380661)

Tromp, J. et al. (2022) Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT‐HF registry. European Journal of Heart Failure, 24(4), pp. 645-652. (doi: 10.1002/ejhf.2431) (PMID:35064730)

Coats, A. J. S. et al. (2022) Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. European Heart Journal, 43(9), pp. 863-867. (doi: 10.1093/eurheartj/ehab834) (PMID:34875053)

Cleland, J. G.F. (2022) Aspirin for primary and secondary prevention of cardiovascular disease: time to stop? Thrombosis and Haemostasis, 122(3), pp. 311-314. (doi: 10.1055/s-0041-1740639) (PMID:35052007)

Ferreira, J. P. et al. (2022) Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. European Heart Journal: Cardiovascular Pharmacotherapy, 8(2), pp. 149-156. (doi: 10.1093/ehjcvp/pvab031) (PMID:33822033)

Jackson, A. M. et al. (2022) Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 24(3), pp. 497-509. (doi: 10.1002/ejhf.2403) (PMID:34918855) (PMCID:PMC9542636)

Sundaram, V. et al. (2022) Hospitalization for heart failure in the USA, UK, Taiwan and Japan: an international comparison of administrative health records on 417,385 individual patients. Journal of Cardiac Failure, 28(3), pp. 353-366. (doi: 10.1016/j.cardfail.2021.08.024) (PMID:34634448)

Masini, G., Graham, F. J., Pellicori, P. , Cleland, J. G.F. , Cuthbert, J. J., Kazmi, S., Inciardi, R. M. and Clark, A. L. (2022) Criteria for iron deficiency in patients with heart failure. Journal of the American College of Cardiology, 79(4), pp. 341-351. (doi: 10.1016/j.jacc.2021.11.039) (PMID:35086656)

Caiazzo, E., Rezig, A. O.M. , Bruzzese, D., Ialenti, A., Cicala, C., Cleland, J. G.F. , Guzik, T. J., Maffia, P. and Pellicori, P. (2022) Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: a systematic review and meta-analysis of randomised trials. Pharmacological Research, 176, 106053. (doi: 10.1016/j.phrs.2021.106053) (PMID:34979235) (PMCID:PMC8719379)

Emmens, J. E. et al. (2022) Worsening renal function in acute heart failure in the context of diuretic response. European Journal of Heart Failure, 24(2), pp. 365-374. (doi: 10.1002/ejhf.2384) (PMID:34786794)

Mujaj, B. et al. (2022) Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis. ESC Heart Failure, 9(1), pp. 685-694. (doi: 10.1002/ehf2.13688) (PMID:34808706) (PMCID:PMC8787993)

Ravassa, S. et al. (2022) Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. European Journal of Heart Failure, 24(2), pp. 321-331. (doi: 10.1002/ejhf.2394) (PMID:34841615)

Ryan, M., Morgan, H., Chiribiri, A., Nagel, E., Cleland, J. and Perera, D. (2022) Myocardial viability testing: all STICHed up, or about to be REVIVED? European Heart Journal, 43(2), pp. 118-126. (doi: 10.1093/eurheartj/ehab729) (PMID:34791132) (PMCID:PMC8757581)

Alnuwaysir, R. I.S. et al. (2022) Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study. European Journal of Heart Failure, 24(1), pp. 192-204. (doi: 10.1002/ejhf.2393) (PMID:34816550)

Cuthbert, J.J. et al. (2022) Hypochloraemia following admission to hospital with heart failure is common and associated with an increased risk of readmission or death: a report from OPERA-HF. European Heart Journal: Acute Cardiovascular Care, 11(1), pp. 43-52. (doi: 10.1093/ehjacc/zuab097) (PMID:34897402)

Ferreira, J. P., Cleland, J. G. , Lam, C. S.P., Anker, S. D., Mehra, M. R., van Veldhuisen, D. J., Byra, W. M., LaPolice, D. A., Greenberg, B. and Zannad, F. (2022) New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial. Clinical Research in Cardiology, 111(1), pp. 50-59. (doi: 10.1007/s00392-021-01891-2) (PMID:34128083)

Lam, P. H. et al. (2022) Right ventricular ejection fraction and beta-blocker effect in heart failure with reduced ejection fraction: Beta-blocker and outcomes in HFrEF by RVEF. Journal of Cardiac Failure, 28(1), pp. 65-70. (doi: 10.1016/j.cardfail.2021.07.026) (PMID:34419597)

Rodríguez-Gómez, I. et al. (2022) Osteoporosis and its association with cardiovascular disease, respiratory disease, and cancer: findings from the UK Biobank prospective cohort study. Mayo Clinic Proceedings, 97(1), pp. 110-121. (doi: 10.1016/j.mayocp.2021.07.019) (PMID:34996542)

Romaine, S. P. R. et al. (2022) Telomere length is independently associated with all-cause mortality in chronic heart failure. Heart, 108(2), pp. 124-129. (doi: 10.1136/heartjnl-2020-318654) (PMID:33789973)

Tromp, J. et al. (2022) A global perspective of racial differences and outcomes in patients presenting with acute heart failure. American Heart Journal, 243, pp. 11-14. (doi: 10.1016/j.ahj.2021.09.001) (PMID:34516969)

Morrow, A. et al. (2022) Prevention and early treatment of the long-term physical effects of COVID-19 in adults: design of a randomised controlled trial of resistance exercise—CISCO-21. Trials, 23, 660. (doi: 10.1186/s13063-022-06632-y) (PMID:35971155) (PMCID:PMC9376905)

2021

Desai, A. S. et al. (2021) Mode of death in patients with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation: Heart Failure, 14(12), e008597. (doi: 10.1161/CIRCHEARTFAILURE.121.008597) (PMID:34807713)

Ferreira, J. P., Girerd, N., Rocca, H.-P. B.-L., Pellicori, P. , Cleland, J. G. , Rossignol, P. and Zannad, F. (2021) No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial = Pas d’influence de la spironolactone sur les concentrations plasmatiques de l’enzyme de conversion de l’angiotensine 2 : résultats de l’essai randomisé HOMAGE. Archives of Cardiovascular Diseases, 114(12), pp. 814-817. (doi: 10.1016/j.acvd.2021.10.003) (PMID:34772647) (PMCID:PMC8576594)

Lota, A. S. et al. (2021) Prognostic significance of nonischaemic myocardial fibrosis in patients with normal left ventricular volumes and ejection-fraction. JACC: Cardiovascular Imaging, 14(12), pp. 2353-2365. (doi: 10.1016/j.jcmg.2021.05.016) (PMID:34274268) (PMCID:PMC8648892)

Lumbers, R. T. et al. (2021) The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 8(6), pp. 5531-5541. (doi: 10.1002/ehf2.13517) (PMID:34480422) (PMCID:PMC8712846)

Cuthbert, J. J., Pellicori, P. , Flockton, R., Kallvikbacka-Bennett, A., Khan, J., Rigby, A. S., Girerd, N., Zannad, F., Cleland, J. G.F. and Clark, A. L. (2021) The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure. European Journal of Heart Failure, 23(11), pp. 1831-1840. (doi: 10.1002/ejhf.2353) (PMID:34632680)

Pan, D. et al. (2021) Prognostic value of the chest x-ray in patients hospitalised for heart failure. Clinical Research in Cardiology, 110(11), pp. 1743-1756. (doi: 10.1007/s00392-021-01836-9) (PMID:33754159)

Täger, T., Atar, D., Agewall, S., Katus, H. A., Grundtvig, M., Cleland, J. G.F. , Clark, A. L., Fröhlich, H. and Frankenstein, L. (2021) Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Heart Failure Reviews, 26(6), pp. 1421-1435. (doi: 10.1007/s10741-020-09954-8) (PMID:32314085) (PMCID:PMC8510986)

Anderson, J. J. et al. (2021) Remote history of VTE is associated with severe COVID-19 in middle and older age: UK Biobank cohort study. Journal of Thrombosis and Haemostasis, 19(10), pp. 2533-2538. (doi: 10.1111/jth.15452) (PMID:34242477) (PMCID:PMC8420476)

Dalal, H., Taylor, R. S. and Cleland, J. G. (2021) Correspondence to European Heart Journal—Quality of Care and Clinical Outcomes in response to paper by Thomas, M. et al. 2021: Predicting the EQ-5D from the Kansas City Cardiomyopathy Questionnaire (KCCQ) in patients with heart failures. European Heart Journal: Quality of Care and Clinical Outcomes, 7(4), e7. (doi: 10.1093/ehjqcco/qcab033) (PMID:33914892) (PMCID:PMC8294675)

Ferreira, J. P. et al. (2021) Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHESUS, and EXAMINE. Clinical Research in Cardiology, 110(10), pp. 1554-1563. (doi: 10.1007/s00392-021-01830-1) (PMID:33686472)

Graham, F. J., Pellicori, P. , Cleland, J. G.F. and Clark, A. L. (2021) Reply to the letter regarding the article 'Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure'. European Journal of Heart Failure, 23(10), pp. 1800-1801. (doi: 10.1002/ejhf.2304) (PMID:34263510)

Meijers, W. C. et al. (2021) Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC). European Journal of Heart Failure, 23(10), pp. 1610-1632. (doi: 10.1002/ejhf.2346) (PMID:34498368)

Pagnesi, M. et al. (2021) Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF. European Journal of Heart Failure, 23(10), pp. 1750-1758. (doi: 10.1002/ejhf.2276) (PMID:34164895)

Papageorgiou, V., Jones, K., Halliday, B. P., Mindham, R., Bruton, J., Wassall, R., Cleland, J. G.F. , Prasad, S. K. and Ward, H. (2021) A qualitative exploration of participant and investigator perspectives from the TRED-HF trial. ESC Heart Failure, 8(5), pp. 3760-3768. (doi: 10.1002/ehf2.13524) (PMID:34390213) (PMCID:PMC8497205)

Raafs, A. et al. (2021) Identification of sex‐specific biomarkers predicting new‐onset heart failure. ESC Heart Failure, 8(5), pp. 3512-3520. (doi: 10.1002/ehf2.13476) (PMID:34156155) (PMCID:PMC8497379)

Shah, P., Abel, A. A.I., Boyalla, V., Pellicori, P. , Kallvikbacka-Bennett, A., Sze, S., Cleland, J. G.F. and Clark, A. L. (2021) A comparison of non-invasive methods of measuring body composition in patients with heart failure: a report from SICA-HF. ESC Heart Failure, 8(5), pp. 3929-3934. (doi: 10.1002/ehf2.13402) (PMID:34216106) (PMCID:PMC8497207)

Cleland, J. G.F. and Pellicori, P. (2021) To master heart failure, first master congestion. Lancet, 398(10304), pp. 935-936. (doi: 10.1016/S0140-6736(21)01914-0) (PMID:34461039)

Ferreira, J. P. et al. (2021) Differences in biomarkers and molecular pathways according to age for patients with HFrEF. Cardiovascular Research, 117(10), pp. 2228-2236. (doi: 10.1093/cvr/cvaa279) (PMID:33002110)

Pellicori, P. and Cleland, J. G.F. (2021) Structural heart disease, cardiac dysfunction and heart failure: the ambiguity of a definition. European Journal of Preventive Cardiology, 28(9), pp. 921-923. (doi: 10.1177/2047487320937135) (PMID:32718235)

McDonagh, T. A. et al. (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 42(36), pp. 3599-3726. (doi: 10.1093/eurheartj/ehab368) (PMID:34447992)

Zakeri, R., Morgan, A. D., Sundaram, V., Bloom, C., Cleland, J. G.F. and Quint, J. K. (2021) Under-recognition of heart failure in patients with atrial fibrillation and the impact of gender: a UK population-based cohort study. BMC Medicine, 19, 179. (doi: 10.1186/s12916-021-02048-8) (PMID:34372832) (PMCID:PMC8353868)

Verdonschot, J. A.J. et al. (2021) Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. Cardiovascular Diabetology, 20, 163. (doi: 10.1186/s12933-021-01357-9)

Ambrosy, A. P., von Haehling, S., Kalra, P. R., Court, E., Bhandari, S., McDonagh, T. and Cleland, J. G.F. (2021) Safety and efficacy of intravenous ferric derisomaltose compared to iron sucrose for iron deficiency anemia in patients with chronic kidney disease with and without heart failure. American Journal of Cardiology, 152, pp. 138-145. (doi: 10.1016/j.amjcard.2021.04.042) (PMID:34162484)

Castrichini, M., Nuzzi, V., Sinagra, G., Cleland, J. and Pellicori, P. (2021) Use of social media by cardiovascular health care professionals: is patient privacy respected? JACC: Cardiovascular Imaging, 14(8), pp. 1680-1682. (doi: 10.1016/j.jcmg.2021.02.012) (PMID:34023252)

Cleland, J. G.F. , Pellicori, P. and González, A. (2021) A novel treatment for heart failure targets myocardial fibrosis. Nature Medicine, 27(8), pp. 1343-1344. (doi: 10.1038/s41591-021-01457-9) (PMID:34385705)

Graham, F. J., Pellicori, P. , Ford, I. , Petrie, M. C. , Kalra, P. R. and Cleland, J. G.F. (2021) Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Clinical Research in Cardiology, 110(8), pp. 1299-1307. (doi: 10.1007/s00392-021-01837-8) (PMID:33755777)

Jorbenadze, A., Fudim, M., Mahfoud, F., Adamson, P. B., Bekfani, T., Wachter, R., Sievert, H., Ponikowski, P. P., Cleland, J. G.F. and Anker, S. D. (2021) Extra-cardiac targets in the management of cardiometabolic disease: device-based therapies. ESC Heart Failure, 8(4), pp. 3327-3338. (doi: 10.1002/ehf2.13361) (PMID:34002946) (PMCID:PMC8318435)

Bistola, V. et al. (2021) Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. European Journal of Heart Failure, 23(7), pp. 1170-1181. (doi: 10.1002/ejhf.2219) (PMID:33998113)

Diaz-Navarro, R., Urrútia, G., Cleland, J. G.F. , Poloni, D., Villagran, F., Acosta-Dighero, R., Bangdiwala, S. I., Rada, G. and Madrid, E. (2021) Stem cell therapy for dilated cardiomyopathy. Cochrane Database of Systematic Reviews, 2021(7), CD013433. (doi: 10.1002/14651858.cd013433.pub2) (PMID:34286511)

Gupta, P. et al. (2021) Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective multicentre study). European Journal of Heart Failure, 23(7), pp. 1182-1190. (doi: 10.1002/ejhf.2160) (PMID:33759308)

Halliday, B. P. et al. (2021) Heart rate as a marker of relapse during withdrawal of therapy in recovered dilated cardiomyopathy. JACC: Heart Failure, 9(7), pp. 509-517. (doi: 10.1016/j.jchf.2021.03.010) (PMID:34119469) (PMCID:PMC8259664)

Lang, N. N. et al. (2021) Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. European Journal of Heart Failure, 23(7), pp. 1147-1155. (doi: 10.1002/ejhf.2138) (PMID:33620131)

Markousis-Mavrogenis, G. et al. (2021) The additive prognostic value of serial plasma interleukin-6 levels over changes in brain natriuretic peptide in patients with acute heart failure. Journal of Cardiac Failure, 27(7), pp. 808-811. (doi: 10.1016/j.cardfail.2021.01.008) (PMID:33497808)

Pellicori, P. et al. (2021) Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial. European Journal of Heart Failure, 23(7), pp. 1085-1093. (doi: 10.1002/ejhf.2220) (PMID:34031968)

Rush, C. J., Cleland, J. G.F. and Veldtman, G. (2021) The emerging burden of heart failure in adults with congenital heart disease. International Journal of Cardiology Congenital Heart Disease, 4, 100171. (doi: 10.1016/j.ijcchd.2021.100171)

Cleland, J. G.F. et al. (2021) The struggle towards a universal definition of heart failure—how to proceed? European Heart Journal, 42(24), pp. 2331-2343. (doi: 10.1093/eurheartj/ehab082) (PMID:33791787)

Pandhi, P. et al. (2021) The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure. Journal of Cachexia, Sarcopenia and Muscle, 12(3), pp. 555-567. (doi: 10.1002/jcsm.12690) (PMID:33742549)

Sierpinski, R. et al. (2021) High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. European Journal of Heart Failure, 23(6), pp. 919-932. (doi: 10.1002/ejhf.2036) (PMID:33111457)

Emmens, J. E. et al. (2021) Impaired high-density lipoprotein function in patients with heart failure. Journal of the American Heart Association, 10(9), e019123. (doi: 10.1161/JAHA.120.019123) (PMID:33870728)

Ferreira, J. P. et al. (2021) Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. European Journal of Heart Failure, 23(5), pp. 776-784. (doi: 10.1002/ejhf.2134) (PMID:33609066)

Mutambudzi, M. et al. (2021) Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants. Occupational and Environmental Medicine, 78(5), pp. 307-314. (doi: 10.1136/oemed-2020-106731) (PMID:33298533)

Pellicori, P. et al. (2021) Ultrasound imaging of congestion in heart failure – examinations beyond the heart. European Journal of Heart Failure, 23(5), pp. 703-712. (doi: 10.1002/ejhf.2032) (PMID:33118672)

Tromp, J. et al. (2021) Global differences in burden and treatment of ischemic heart disease in acute heart failure: REPORT-HF. JACC: Heart Failure, 9(5), pp. 349-359. (doi: 10.1016/j.jchf.2020.12.015) (PMID:33839078)

Wolsk, E. et al. (2021) Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 23(5), pp. 754-764. (doi: 10.1002/ejhf.2146) (PMID:33686716)

Zhang, J., Pellicori, P. , Schutte, R. and Cleland, J.G. (2021) The association between blood groups and COVID-19 infection: a study from the UK Biobank. Journal of Internal Medicine, 289(5), pp. 747-748. (doi: 10.1111/joim.13226) (PMID:33306225)

Coats, A. J. et al. (2021) The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. European Heart Journal, 42(13), pp. 1254-1269. (doi: 10.1093/eurheartj/ehab086) (PMID:33734354) (PMCID:PMC8014526)

Ferreira, J. P., Lam, C. S. P., Anker, S. D., Mehra, M. R., van Veldhuisen, D. J., Byra, W. M., La Police, D. A., Cleland, J. G.F. , Greenberg, B. and Zannad, F. (2021) Plasma D‐dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER‐HF trial. European Journal of Heart Failure, 23(4), pp. 648-656. (doi: 10.1002/ejhf.2003) (PMID:32959502)

Ferreira, J. P. et al. (2021) Proteomic and mechanistic analysis of spironolactone in patients at risk for HF. JACC: Heart Failure, 9(4), pp. 268-277. (doi: 10.1016/j.jchf.2020.11.010) (PMID:33549556)

Uijl, A., Vaartjes, I., Denaxas, S., Hemingway, H., Shah, A. D., Cleland, J. , Grobbee, D. E., Hoes, A. W., Asselbergs, F. W. and Koudstaal, S. (2021) Temporal trends in heart failure medication prescription in a population-based cohort study. BMJ Open, 11(3), e043290. (doi: 10.1136/bmjopen-2020-043290) (PMID:33653753) (PMCID:PMC7929882)

Ferreira, J. P. et al. (2021) Impact of geographic region on the COMMANDER-HF Trial. JACC: Heart Failure, 9(3), pp. 201-211. (doi: 10.1016/j.jchf.2020.11.007) (PMID:33549557)

Mordi, I. R. et al. (2021) Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF. European Journal of Heart Failure, 23(3), pp. 436-444. (doi: 10.1002/ejhf.1799) (PMID:32216000)

Pellicori, P. et al. (2021) COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database of Systematic Reviews, 2021(3), CD013879. (doi: 10.1002/14651858.CD013879) (PMID:33704775)

Smart, N. A., Pearson, M. J., Taylor, R. S. and Cleland, J. (2021) Exercise training for heart failure with preserved ejection fraction (ExTraMATCH III): protocol for an individual patient data meta-analysis. Journal of Clinical Exercise Physiology, 10(1), pp. 3-11. (doi: 10.31189/2165-7629-10.1.3)

Cleland, J. G.F. et al. (2021) The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. European Heart Journal, 42(6), pp. 684-696. (doi: 10.1093/eurheartj/ehaa758) (PMID:33215209) (PMCID:PMC7878013)

Felker, G. M. et al. (2021) Effects of a novel nitroxyl donor in acute heart failure: the STAND-UP AHF Study. JACC: Heart Failure, 9(2), pp. 146-157. (doi: 10.1016/j.jchf.2020.10.012) (PMID:33248986)

Halliday, B. P. et al. (2021) Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy – insights from TRED‐HF. European Journal of Heart Failure, 23(2), pp. 293-301. (doi: 10.1002/ejhf.2063) (PMID:33225554)

Samuel, N. A., Cuthbert, J. J., Brown, O. I., Kazmi, S., Cleland, J. G.F. , Rigby, A. S. and Clark, A. L. (2021) Relation between thyroid function and mortality in patients with chronic heart failure. American Journal of Cardiology, 139, pp. 57-63. (doi: 10.1016/j.amjcard.2020.10.034) (PMID:33115640)

Teerlink, J. R. et al. (2021) Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. New England Journal of Medicine, 384, pp. 105-116. (doi: 10.1056/NEJMoa2025797) (PMID:33185990)

Bekfani, T. et al. (2021) A current and future outlook on upcoming technologies in the remote monitoring of patients with heart failure. European Journal of Heart Failure, 23(1), pp. 175-185. (doi: 10.1002/ejhf.2033) (PMID:33111389)

Davison, B. A. et al. (2021) Is acute heart failure a distinctive disorder? An analysis from BIOSTAT‐CHF. European Journal of Heart Failure, 23(1), pp. 43-57. (doi: 10.1002/ejhf.2077) (PMID:33340221)

He, T. et al. (2021) Serum and urinary biomarkers of collagen type‐I turnover predict prognosis in patients with heart failure. Clinical and Translational Medicine, 11(1), e267. (doi: 10.1002/ctm2.267) (PMID:33463057) (PMCID:PMC7803349)

Anderson, J. J. et al. (2021) Ethnic differences in prevalence of actionable HbA1c levels in UK Biobank: implications for screening. BMJ Open Diabetes Research and Care, 9(1), e002176. (doi: 10.1136/bmjdrc-2021-002176) (PMID:34353880) (PMCID:PMC8344314)

Shoaib, A. et al. (2021) Substantial decline in hospital admissions for heart failure accompanied by increased community mortality during COVID-19 pandemic. European Heart Journal: Quality of Care and Clinical Outcomes, 7(4), pp. 378-387. (doi: 10.1093/ehjqcco/qcab040) (PMID:34043762) (PMCID:PMC8244536)

2020

Purcell, C. , Daw, P., Kerr, C., Cleland, J. , Cowie, A., Dalal, H., Ibbotson, T. , Murphy, C. and Taylor, R. (2020) Protocol for an implementation study of an evidence-based home cardiac rehabilitation programme for people with heart failure and their caregivers in Scotland (SCOT:REACH-HF). BMJ Open, 10(12), e040771. (doi: 10.1136/bmjopen-2020-040771) (PMID:33277287) (PMCID:PMC7722379)

Brown, O., Costanzo, P., Clark, A. L., Condorelli, G., Cleland, J. G.F. , Sathyapalan, T., Hepburn, D., Kilpatrick, E. S. and Atkin, S. L. (2020) Relationship between a single measurement at baseline of body mass index, glycated hemoglobin, and the risk of mortality and cardiovascular morbidity in type 2 diabetes mellitus. Cardiovascular Endocrinology and Metabolism, 9(4), pp. 177-182. (doi: 10.1097/XCE.0000000000000202) (PMID:33225234) (PMCID:PMC7673766)

Felker, G. M., Solomon, S. D., McMurray, J. J.V. , Cleland, J. G.F. , Abbasi, S. A., Malik, F. I., Zhang, H., Globe, G. and Teerlink, J. R. (2020) Effects of omecamtiv mecarbil on symptoms and health-related quality of life in patients with chronic heart failure: results from the COSMIC-HF study. Circulation: Heart Failure, 13(12), e007814. (doi: 10.1161/CIRCHEARTFAILURE.120.007814) (PMID:33176437) (PMCID:PMC7742205)

Psotka, M. A. et al. (2020) Conduct of clinical trials in the era of COVID-19: JACC scientific expert panel. Journal of the American College of Cardiology, 76(20), pp. 2368-2378. (doi: 10.1016/j.jacc.2020.09.544) (PMID:33183511)

Selvaraj, S. et al. (2020) Serum uric acid, influence of sacubitril/valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. European Journal of Heart Failure, 22(11), pp. 2093-2101. (doi: 10.1002/ejhf.1984) (PMID:32840930)

Teerlink, J. R. et al. (2020) Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 22(11), pp. 2160-2171. (doi: 10.1002/ejhf.2015) (PMID:32985088) (PMCID:PMC7756903)

Rahimi, K., Nazarzadeh, M., Pinho-Gomes, A.-C., Woodward, M., Salimi-Khorshidi, G., Ohkuma, T., Fitzpatrick, R., Tarassenko, L., Denis, M. and Cleland, J. (2020) Home monitoring with technology-supported management in chronic heart failure: a randomised trial. Heart, 106(20), pp. 1573-1578. (doi: 10.1136/heartjnl-2020-316773) (PMID:32580977)

von Haehling, S. et al. (2020) Muscle wasting as an independent predictor of survival in patients with chronic heart failure. Journal of Cachexia, Sarcopenia and Muscle, 11(5), pp. 1242-1249. (doi: 10.1002/jcsm.12603) (PMID:32767518) (PMCID:PMC7567155)

Pellicori, P. et al. (2020) Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. European Journal of Heart Failure, 22(9), pp. 1711-1723. (doi: 10.1002/ejhf.1716) (PMID:31950604)

Voors, A. A. et al. (2020) Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. European Journal of Heart Failure, 22(9), pp. 1649-1658. (doi: 10.1002/ejhf.1933) (PMID:32558989) (PMCID:PMC7689751)

Bomer, N. et al. (2020) Selenium and outcome in heart failure. European Journal of Heart Failure, 22(8), pp. 1415-1423. (doi: 10.1002/ejhf.1644) (PMID:31808274) (PMCID:PMC7540257)

Lombardi, C. M. et al. (2020) Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. Clinical Research in Cardiology, 109, pp. 967-977. (doi: 10.1007/s00392-019-01588-7) (PMID:31996990)

Ouwerkerk, W. et al. (2020) Effects of combined renin–angiotensin–aldosterone system inhibitor and beta‐blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT‐CHF and ASIAN‐HF registries. European Journal of Heart Failure, 22(8), pp. 1472-1482. (doi: 10.1002/ejhf.1869) (PMID:32583922)

Shi, C. et al. (2020) Tumor biomarkers: association with heart failure outcomes. Journal of Internal Medicine, 288(2), pp. 207-218. (doi: 10.1111/joim.13053) (PMID:32372544)

ter Maaten, J. M. et al. (2020) Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. Clinical Research in Cardiology, 109, pp. 1048-1059. (doi: 10.1007/s00392-020-01598-w) (PMID:32002631) (PMCID:PMC7375987)

Cleland, J. G.F. , Li, C. and Jones, Y. (2020) Artificial intelligence needs clinical intelligence to succeed. JACC: Heart Failure, 8(7), pp. 588-591. (doi: 10.1016/j.jchf.2020.06.002) (PMID:32616167)

Taya, U. et al. (2020) Predictors of left ventricular remodelling in patients with dilated cardiomyopathy - a cardiovascular magnetic resonance study. European Journal of Heart Failure, 22(7), pp. 1160-1170. (doi: 10.1002/ejhf.1734) (PMID:32056322)

Cleland, J. G.F. , Lyon, A. R., McDonagh, T. and McMurray, J. J.V. (2020) The year in cardiology 2019: heart failure. Romanian Journal of Cardiology, 30(2), pp. 185-204. (doi: 10.47803/rjc.2020.30.2.185)

Anker, S. D. et al. (2020) Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an expert consensus position paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 41(22), pp. 2109-2117. (doi: 10.1093/eurheartj/ehaa461) (PMID:32498081)

Katus, H. A., Cleland, J. G.F. and Jaffe, A. S. (2020) Myocardial injury in severe COVID-19 infection. European Heart Journal, 41(22), pp. 2080-2082. (doi: 10.1093/eurheartj/ehaa447) (PMID:32464642)

Cleland, J. G.F. , Clark, R. A., Pellicori, P. and Inglis, S. C. (2020) Caring for people with heart failure and many other medical problems through and beyond the COVID‐19 pandemic; the advantages of universal‐access to home telemonitoring. European Journal of Heart Failure, 22(6), pp. 995-998. (doi: 10.1002/ejhf.1864) (PMID:32385954) (PMCID:PMC7273055)

Sama, I. E. et al. (2020) A network analysis to identify pathophysiological pathways distinguishing ischemic from non-ischemic heart failure. European Journal of Heart Failure, 22(5), pp. 821-833. (doi: 10.1002/ejhf.1811) (PMID:32243695)

Voors, A. A. et al. (2020) Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors. European Heart Journal, 41(19), pp. 1810-1817. (doi: 10.1093/eurheartj/ehaa373) (PMID:32388565) (PMCID:PMC7239195)

Cunningham, J. W. et al. (2020) Natriuretic peptide-based inclusion criteria in a heart failure clinical trial: insights from COMMANDER HF. JACC: Heart Failure, 8(5), pp. 359-368. (doi: 10.1016/j.jchf.2019.12.009) (PMID:32171760) (PMCID:PMC7151428)

Fudim, M. et al. (2020) Future research prioritization in cardiac resynchronization therapy. American Heart Journal, 223, pp. 48-58. (doi: 10.1016/j.ahj.2020.02.011) (PMID:32163753)

Quint, J. K. et al. (2020) Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006–2015. European Heart Journal, 41(17), pp. 1636-1649. (doi: 10.1093/eurheartj/ehz880) (PMID:31883328)

Stienen, S., Ferreira, J. P., Pitt, B., Cleland, J. G. , Pellicori, P. , Girerd, N., Rossignol, P. and Zannad, F. (2020) Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure. European Journal of Heart Failure, 22(5), pp. 901-903. (doi: 10.1002/ejhf.1812) (PMID:32243646)

Pandhi, P. et al. (2020) Clinical value of pre‐discharge bio‐adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. European Journal of Heart Failure, 22(4), pp. 683-691. (doi: 10.1002/ejhf.1693) (PMID:31797505)

Cleland, J. G.F. , Lyon, A. R., McDonagh, T. and McMurray, J. J.V. (2020) The year in cardiology: heart failure. European Heart Journal, 41(12), pp. 1232-1248. (doi: 10.1093/eurheartj/ehz949) (PMID:31901936) (PMCID:PMC7084174)

Wehner, G. J. et al. (2020) Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? European Heart Journal, 41(12), pp. 1249-1257. (doi: 10.1093/eurheartj/ehz550) (PMID:31386109)

Santema, B. T. et al. (2020) The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. Clinical Research in Cardiology, 109, pp. 331-338. (doi: 10.1007/s00392-019-01513-y) (PMID:31263996) (PMCID:PMC7042190)

Tromp, J. et al. (2020) Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. Lancet Global Health, 8(3), e411-e422. (doi: 10.1016/S2214-109X(20)30004-8) (PMID:32087174)

Bégué, C. et al. (2020) Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy. Heart, 106(3), pp. 196-202. (doi: 10.1136/heartjnl-2019-314826) (PMID:31350276)

Welsh, C. et al. (2020) Glycated hemoglobin, prediabetes and the links to cardiovascular disease: data from UK Biobank. Diabetes Care, 43(2), pp. 440-445. (doi: 10.2337/dc19-1683) (PMID:31852727)

Filippatos, G. et al. (2020) Global differences in characteristics, precipitants, and initial management of patients presenting with acute heart failure. JAMA Cardiology, 5(4), pp. 401-410. (doi: 10.1001/jamacardio.2019.5108) (PMID:31913404)

Anker, M. S., Hülsmann, M. and Cleland, J. G. (2020) What do patients with heart failure die from? A single assassin or a conspiracy? European Journal of Heart Failure, 22(1), pp. 26-28. (doi: 10.1002/ejhf.1689) (PMID:31863684)

Cao, T. H. et al. (2020) Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. European Journal of Heart Failure, 22(1), pp. 70-80. (doi: 10.1002/ejhf.1608) (PMID:31692186) (PMCID:PMC7028019)

Ferreira, J. P. et al. (2020) Cardiovascular and non‐cardiovascular death distinction: the utility of troponin beyond N‐terminal pro‐B‐type natriuretic peptide. Findings from the BIOSTAT‐CHF study. European Journal of Heart Failure, 22(1), pp. 81-89. (doi: 10.1002/ejhf.1654) (PMID:31793144)

Kobayashi, M. et al. (2020) Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. European Journal of Internal Medicine, 71, pp. 62-69. (doi: 10.1016/j.ejim.2019.10.017) (PMID:31708361)

Nikolaidou, T., Samuel, N. A., Marincowitz, C., Fox, D. J., Cleland, J. G.F. and Clark, A. L. (2020) Electrocardiographic characteristics in patients with heart failure and normal ejection fraction: a systematic review and meta‐analysis. Annals of Noninvasive Electrocardiology, 25(1), e12710. (doi: 10.1111/anec.12710) (PMID:31603593) (PMCID:PMC7358891)

Pellicori, P. , Cleland, J. G.F. and Clark, A. L. (2020) Chronic obstructive pulmonary disease and heart failure: a breathless conspiracy. Heart Failure Clinics, 16(1), pp. 33-44. (doi: 10.1016/j.hfc.2019.08.003) (PMID:31735313)

Pellicori, P. , Khan, M. J. I., Graham, F. J. and Cleland, J. G.F. (2020) New perspectives and future directions in the treatment of heart failure. Heart Failure Reviews, 25, pp. 147-159. (doi: 10.1007/s10741-019-09829-7) (PMID:31327116) (PMCID:PMC6985084)

Pellicori, P. , Zhang, J., Cuthbert, J., Urbinati, A., Shah, P., Kazmi, S., Clark, A. L. and Cleland, J. G.F. (2020) High sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death. Cardiovascular Research, 116(1), pp. 91-100. (doi: 10.1093/cvr/cvz198) (PMID:31350553)

Israr, M. Z. et al. (2020) Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT‐CHF. European Journal of Heart Failure, 22(8), pp. 1486-1490. (doi: 10.1002/ejhf.1951) (PMID:32666670)

2019

Kotecha, D. et al. (2019) Impact of renal impairment on beta-blocker efficacy in patients with heart failure. Journal of the American College of Cardiology, 74(23), pp. 2893-2904. (doi: 10.1016/j.jacc.2019.09.059) (PMID:31806133)

Johnson, M. J. et al. (2019) Oral modified release morphine for breathlessness in chronic heart failure: a randomised placebo-controlled trial. ESC Heart Failure, 6(6), pp. 1149-1160. (doi: 10.1002/ehf2.12498) (PMID:31389157) (PMCID:PMC6989293)

Mehra, M. R. et al. (2019) A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal, 40(44), pp. 3593-3602. (doi: 10.1093/eurheartj/ehz427) (PMID:31461239) (PMCID:PMC6868495)

Beldhuis, I. E. et al. (2019) Trajectories of changes in renal function in patients with acute heart failure. Journal of Cardiac Failure, 25(11), pp. 866-874. (doi: 10.1016/j.cardfail.2019.07.004) (PMID:31319165)

Beusekamp, J. C. et al. (2019) Hyperkalemia and treatment with RAAS inhibitors during acute heart failure hospitalizations and their association with mortality. JACC: Heart Failure, 7(11), pp. 970-979. (doi: 10.1016/j.jchf.2019.07.010) (PMID:31606364)

Conrad, N., Judge, A., Canoy, D., Tran, J., Pinho-Gomes, A. C., Millett, E. R.C., Salimi-Khorshidi, G., Cleland, J. G. , McMurray, J. J.V. and Rahimi, K. (2019) Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86 000 individuals. JAMA Cardiology, 4(11), pp. 1102-1111. (doi: 10.1001/jamacardio.2019.3593) (PMID:31479100) (PMCID:PMC6724155)

Lees, J. S. et al. (2019) Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease. Nature Medicine, 25, pp. 1753-1760. (doi: 10.1038/s41591-019-0627-8) (PMID:31700174) (PMCID:PMC6858876)

Pellicori, P. , Urbinati, A., Kaur, K., Zhang, J., Shah, P., Kazmi, S., Capucci, A., Cleland, J. G.F. and Clark, A. L. (2019) Prevalence and incidence of atrial fibrillation in ambulatory patients with heart failure. American Journal of Cardiology, 124(10), pp. 1554-1560. (doi: 10.1016/j.amjcard.2019.08.018) (PMID:31558271)

Sillars, A. et al. (2019) Association of fitness and grip-strength with heart failure: findings from the UK Biobank population-based study. Mayo Clinic Proceedings, 94(11), pp. 2230-2240. (doi: 10.1016/j.mayocp.2019.04.041) (PMID:31685151)

Solomon, S. D. et al. (2019) Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine, 381, pp. 1609-1620. (doi: 10.1056/NEJMoa1908655) (PMID:31475794)

Santema, B. T. et al. (2019) Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet, 394, 10205. (doi: 10.1016/S0140-6736(19)31792-1) (PMID:31447116)

Seferovic, P. M. et al. (2019) Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 21(10), pp. 1169-1186. (doi: 10.1002/ejhf.1531) (PMID:31129923)

Yazaki, Y. et al. (2019) Geographical location affects the levels and association of trimethylamine N‐oxide with heart failure mortality in BIOSTAT‐CHF: a post‐hoc analysis. European Journal of Heart Failure, 21(10), pp. 1291-1294. (doi: 10.1002/ejhf.1550) (PMID:31353762)

Metra, M. et al. (2019) Effects of serelaxin in patients with acute heart failure. New England Journal of Medicine, 381(8), pp. 716-726. (doi: 10.1056/NEJMoa1801291) (PMID:31433919)

Täger, T. et al. (2019) Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure – a multicenter propensity score matched analysis. International Journal of Cardiology, 289, pp. 83-90. (doi: 10.1016/j.ijcard.2019.01.109) (PMID:30827731)

Cleland, J. G.F. and Pellicori, P. (2019) Myocardial dysfunction and coronary artery disease as therapeutic targets in heart failure. Circulation, 140(7), pp. 538-541. (doi: 10.1161/CIRCULATIONAHA.119.041523) (PMID:31403847)

Welsh, C. et al. (2019) Comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease: data from UK Biobank. Circulation, 140(7), pp. 542-552. (doi: 10.1161/CIRCULATIONAHA.119.041149) (PMID:31216866) (PMCID:PMC6693929)

Felker, G. M., Borentain, M., Cleland, J. G.F. , DeSouza, M. M., Kessler, P. D., O'Connor, C. M., Seiffert, D., Teerlink, J. R., Voors, A. A. and McMurray, J. J.V. (2019) Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. European Journal of Heart Failure, 21(8), pp. 1022-1031. (doi: 10.1002/ejhf.1504) (PMID:31168885)

Fröhlich, H. et al. (2019) Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe. Heart, 105(16), pp. 1252-1259. (doi: 10.1136/heartjnl-2018-314256) (PMID:30792238)

Halliday, B. P. et al. (2019) Outcome in dilated cardiomyopathy related to the extent, location and pattern of late gadolinium enhancement. JACC: Cardiovascular Imaging, 12(8 Pt 2), pp. 1645-1655. (doi: 10.1016/j.jcmg.2018.07.015) (PMID:30219397) (PMCID:PMC6682609)

Markousis-Mavrogenis, G. et al. (2019) The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF Study. European Journal of Heart Failure, 21(8), pp. 965-973. (doi: 10.1002/ejhf.1482) (PMID:31087601)

Halliday, B. P., Cleland, J. G.F. and Prasad, S. K. (2019) When can heart failure treatment be stopped safely? – Authors' reply. Lancet, 394(10194), pp. 217-218. (doi: 10.1016/S0140-6736(19)30499-4)

Rankin, J., Rowen, D., Howe, A., Cleland, J. G.F. and Whitty, J. A. (2019) Valuing health-related quality of life in heart failure: a systematic review of methods to derive quality-adjusted life years (QALYs) in trial-based cost–utility analyses. Heart Failure Reviews, 24(4), pp. 549-563. (doi: 10.1007/s10741-019-09780-7) (PMID:30903357) (PMCID:PMC6560006)

Beverborg, N. G., van der Wal, H., Klip, I. T., Anker, S. D., Cleland, J. G.F. , Dickstein, K., van Veldhuisen, D. J., Voors, A. A. and van der Meer, P. (2019) Differences in clinical profile and outcomes of low iron storage vs defective iron utilization in patients with heart failure: results from the DEFINE-HF and BIOSTAT-CHF studies. JAMA Cardiology, 4(7), pp. 696-701. (doi: 10.1001/jamacardio.2019.1739) (PMID:31188392) (PMCID:PMC6563589)

Cleland, J. G.F. , Hindricks, G. and Petrie, M. (2019) The shocking lack of evidence for implantable cardioverter defibrillators for heart failure; with or without cardiac resynchronization. European Heart Journal, 40(26), pp. 2128-2130. (doi: 10.1093/eurheartj/ehz409) (PMID:31257403)

Mordi, I. R. et al. (2019) Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. Clinical Research in Cardiology, 108(7), pp. 797-805. (doi: 10.1007/s00392-018-1409-x) (PMID:30610382) (PMCID:PMC6584244)

Nuzzi, V. et al. (2019) Clinical and prognostic association of total atrial conduction time in patients with heart failure: a report from Studies Investigating Co-morbidities Aggravating Heart Failure. Journal of Cardiovascular Medicine, 20(7), pp. 442-449. (doi: 10.2459/JCM.0000000000000802) (PMID:30985354)

Pellicori, P. , Shah, P., Cuthbert, J., Urbinati, A., Zhang, J., Kallvikbacka-Bennett, A., Clark, A. L. and Cleland, J. G.F. (2019) Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure. European Journal of Heart Failure, 21(7), pp. 904-916. (doi: 10.1002/ejhf.1383) (PMID:30666769)

Suzuki, T. et al. (2019) Association with outcomes and response to treatment of trimethylamine N‐oxide in heart failure (from BIOSTAT‐CHF). European Journal of Heart Failure, 21(7), pp. 877-886. (doi: 10.1002/ejhf.1338) (PMID:30370976)

Shoaib, A. et al. (2019) Characteristics and outcome of acute heart failure patients according to the severity of peripheral oedema. International Journal of Cardiology, 285, pp. 40-46. (doi: 10.1016/j.ijcard.2019.03.020) (PMID:30905515)

Greenberg, B. et al. (2019) Association of rivaroxaban with thromboembolic events in patients with heart failure, coronary disease, and sinus rhythm: a post hoc analysis of the COMMANDER HF trial. JAMA Cardiology, 4(6), pp. 515-523. (doi: 10.1001/jamacardio.2019.1049) (PMID:31017637) (PMCID:PMC6487904)

House, A. A. et al. (2019) Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies conference. Kidney International, 95(6), pp. 1304-1317. (doi: 10.1016/j.kint.2019.02.022) (PMID:31053387)

Mueller, C. et al. (2019) Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European Journal of Heart Failure, 21(6), pp. 715-731. (doi: 10.1002/ejhf.1494) (PMID:31222929)

ter Maaten, J. M. et al. (2019) Bio‐adrenomedullin as a marker of congestion in patients with new‐onset and worsening heart failure. European Journal of Heart Failure, 21(6), pp. 732-743. (doi: 10.1002/ejhf.1437) (PMID:30843353)

Raber, I., McCarthy, C. P., Vaduganathan, M., Bhatt, D. L., Wood, D. A., Cleland, J. G.F. , Blumenthal, R. S. and McEvoy, J. W. (2019) The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet, 393(10186), pp. 2155-2167. (doi: 10.1016/S0140-6736(19)30541-0)

Cleland, J. G.F. , Pellicori, P. and Clark, A. L. (2019) Prevention or procrastination for heart failure?: Why we need a universal definition of heart failure. Journal of the American College of Cardiology, 73(19), pp. 2398-2400. (doi: 10.1016/j.jacc.2019.03.471) (PMID:31097158)

Conrad, N. et al. (2019) Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: a cohort study of 93,000 UK patients. PLoS Medicine, 16(5), e1002805. (doi: 10.1371/journal.pmed.1002805) (PMID:31112552) (PMCID:PMC6528949)

Ferreira, J. P. et al. (2019) Proteomic bioprofiles and mechanistic pathways of progression to heart failure: the HOMAGE study. Circulation, 12(5), e005897. (doi: 10.1161/CIRCHEARTFAILURE.118.005897) (PMID:31104495)

Shoaib, A. et al. (2019) Mode of presentation and mortality amongst patients hospitalized with heart failure? A report from The First Euro Heart Failure Survey. Clinical Research in Cardiology, 108(5), pp. 510-519. (doi: 10.1007/s00392-018-1380-6) (PMID:30361818) (PMCID:PMC6484773)

Anderson, S. G., Shoaib, A., Myint, P. K., Cleland, J. G. , Hardman, S. M., McDonagh, T. A., Dargie, H., Keavney, B., Garratt, C. J. and Mamas, M. A. (2019) Does rhythm matter in Acute Heart Failure? An insight from the British Society for Heart Failure National Audit. Clinical Research in Cardiology, (doi: 10.1007/s00392-019-01463-5) (PMID:30963233)

Sokoreli, I., Cleland, J.G. , Pauws, S.C., Steyerberg, E.W., de Vries, J.J.G., Riistama, J.M., Dobbs, K., Bulemfu, J. and Clark, A.L. (2019) Added value of frailty and social support in predicting risk of 30-day unplanned re-admission or death for patients with heart failure: an analysis from OPERA-HF. International Journal of Cardiology, 278, pp. 167-172. (doi: 10.1016/j.ijcard.2018.12.030) (PMID:30587417)

de Boer, R. A. et al. (2019) Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 21(3), pp. 272-285. (doi: 10.1002/ejhf.1406) (PMID:30714667) (PMCID:PMC6607480)

Cleland, J. G.F. , van Veldhuisen, D. J. and Ponikowski, P. (2019) The year in cardiology 2018: heart failure. European Heart Journal, 40(8), pp. 651-661. (doi: 10.1093/eurheartj/ehz010) (PMID:30778534)

Bekfani, T. et al. (2019) Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life. Clinical Research in Cardiology, 108(2), pp. 203-211. (doi: 10.1007/s00392-018-1344-x) (PMID:30051186)

Ferreira, J. P. et al. (2019) Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study. European Journal of Heart Failure, 21(2), pp. 218-226. (doi: 10.1002/ejhf.1380) (PMID:30600578)

Ferreira, J. P. et al. (2019) Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. Heart, 105(4), pp. 307-314. (doi: 10.1136/heartjnl-2018-313182) (PMID:30121630)

Zhang, J., Begley, A., Jackson, R., Harrison, M., Pellicori, P. , Clark, A. L. and Cleland, J. G.F. (2019) Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose–response meta-analysis. Clinical Research in Cardiology, 108(2), pp. 119-132. (doi: 10.1007/s00392-018-1302-7) (PMID:29951802)

Ambrosy, A. P. et al. (2019) Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. European Journal of Heart Failure, 21(3), pp. 373-381. (doi: 10.1002/ejhf.1404) (PMID:30698316)

Keeble, T. R. et al. (2019) Percutaneous haemodynamic and renal support in patients presenting with decompensated heart failure: A multi-centre efficacy study using the Reitan Catheter Pump (RCP). International Journal of Cardiology, 275, pp. 53-58. (doi: 10.1016/j.ijcard.2018.09.085) (PMID:30342873)

Halliday, B. P. et al. (2019) Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet, 393(10166), pp. 61-73. (doi: 10.1016/S0140-6736(18)32484-X) (PMID:30429050) (PMCID:PMC6319251)

2018

Abuosa, A. M., Elshiekh, A. H., Qureshi, K., Abrar, M. B., Kholeif, M. A., Kinsara, A. J., Andejani, A., Ahmed, A. H. and Cleland, J. G.F. (2018) Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin. Indian Heart Journal, 70(S3), S96-S100. (doi: 10.1016/j.ihj.2018.06.011) (PMID:30595329)

Shiraishi, Y. et al. (2018) Outcome of hospitalised heart failure in Japan and the United Kingdom stratified by plasma N-terminal pro-B-type natriuretic peptide. Clinical Research in Cardiology, 107(12), pp. 1103-1110. (doi: 10.1007/s00392-018-1283-6) (PMID:29785543)

Tromp, J. et al. (2018) Novel endotypes in heart failure: effects on guideline-directed medical therapy. European Heart Journal, 39(48), pp. 4269-4276. (doi: 10.1093/eurheartj/ehy712) (PMID:30551207)

Streng, K. W. et al. (2018) Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology, 271, pp. 132-139. (doi: 10.1016/j.ijcard.2018.04.001)

Santema, B. T. et al. (2018) Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. European Heart Journal, 39(43), pp. 3867-3875. (doi: 10.1093/eurheartj/ehy421) (PMID:30137304)

Cao, T. H. et al. (2018) Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. Clinical Proteomics, 15, 35. (doi: 10.1186/s12014-018-9213-1) (PMID:30410428) (PMCID:PMC6214161)

Narang, R. et al. (2018) Prevalence and determinants of hypertension in apparently healthy schoolchildren in India: a multi-center study. European Journal of Preventive Cardiology, 25(16), pp. 1775-1784. (doi: 10.1177/2047487318790056) (PMID:30043628)

Zhang, J., Pellicori, P. , Pan, D., Dierckx, R., Clark, A.L. and Cleland, J.G.F. (2018) Dynamic risk stratification using serial measurements of plasma concentrations of natriuretic peptides in patients with heart failure. International Journal of Cardiology, 269, pp. 196-200. (doi: 10.1016/j.ijcard.2018.06.070) (PMID:30001941)

Maack, C. et al. (2018) Treatments targeting inotropy. European Heart Journal, ehy600. (doi: 10.1093/eurheartj/ehy600) (PMID:30295807)

Zannad, F. et al. (2018) Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. New England Journal of Medicine, 379, pp. 1332-1342. (doi: 10.1056/NEJMoa1808848) (PMID:30146935)

Halliday, B. P. et al. (2018) Sex and age-based differences in the natural history and outcome of dilated cardiomyopathy. European Journal of Heart Failure, 20(10), pp. 1392-1400. (doi: 10.1002/ejhf.1216) (PMID:29862606) (PMCID:PMC6392171)

Keene, D. et al. (2018) Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPE-HF) trial. ESC Heart Failure, 5(5), pp. 965-976. (doi: 10.1002/ehf2.12315) (PMID:29984912) (PMCID:PMC6165934)

Shah, S. J. et al. (2018) One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure (REDUCE LAP-HF I) trial: a randomized clinical trial. JAMA Cardiology, 3(10), pp. 968-977. (doi: 10.1001/jamacardio.2018.2936) (PMID:30167646) (PMCID:PMC6233816)

Cleland, J. G.F. and Clark, R. A. (2018) Telehealth: delivering high-quality care for heart failure. Lancet, 392(10152), pp. 990-991. (doi: 10.1016/S0140-6736(18)31995-0) (PMID:30153986)

Nagai, T. et al. (2018) Mortality after admission for heart failure in the United Kingdom compared to Japan. Open Heart, 5, e000811. (doi: 10.1136/openhrt-2018-000811) (PMID:30228905) (PMCID:PMC6135420)

Tromp, J. et al. (2018) Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction. Journal of the American College of Cardiology, 72(10), pp. 1081-1090. (doi: 10.1016/j.jacc.2018.06.050) (PMID:30165978)

Panahi, M. et al. (2018) Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition. Cardiovascular Research, 114(11), pp. 1445-1461. (doi: 10.1093/cvr/cvy145) (PMID:30010800) (PMCID:PMC6106100)

Williams, B. et al. (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 39(33), pp. 3021-3104. (doi: 10.1093/eurheartj/ehy339) (PMID:30165516)

Gulati, A. et al. (2018) Absence of myocardial fibrosis predicts favorable long-term survival in new-onset heart failure: a cardiovascular magnetic resonance study. Circulation: Cardiovascular Imaging, 11(9), e007722. (doi: 10.1161/CIRCIMAGING.118.007722) (PMID:30354674)

Streng, K. W. et al. (2018) Waist-to-hip ratio and mortality in heart failure. European Journal of Heart Failure, 20(9), pp. 1269-1277. (doi: 10.1002/ejhf.1244) (PMID:29963737)

Nagai, T. et al. (2018) Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan. European Journal of Heart Failure, 20(8), pp. 1179-1190. (doi: 10.1002/ejhf.1210) (PMID:29846026)

Nichols, S., Gleadall-Siddall, D.O., Antony, R., Clark, A.L., Cleland, J.G.F. , Carroll, S. and Ingle, L. (2018) Estimated peak functional capacity: an accurate method for assessing change in peak oxygen consumption after cardiac rehabilitation? Clinical Physiology and Functional Imaging, 38(4), pp. 681-688. (doi: 10.1111/cpf.12468) (PMID:28857391)

Palazzuoli, A., Ruocco, G., Beltrami, M., Nuti, R. and Cleland, J. G. (2018) Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF. Clinical Research in Cardiology, 107(7), pp. 586-596. (doi: 10.1007/s00392-018-1221-7) (PMID:29532155)

Pellicori, P. , Cleland, J. G.F. and Clark, A. L. (2018) Losing track by tracking speckles. JACC: Cardiovascular Imaging, 11(7), pp. 1038-1039. (doi: 10.1016/j.jcmg.2018.04.027) (PMID:29976301)

Sartor, F., Papini, G., Cox, L. G. E. and Cleland, J. (2018) Methodological shortcomings of wrist-worn heart rate monitors validations. Journal of Medical Internet Research, 20(7), e10108. (doi: 10.2196/10108) (PMID:29967000)

Solomon, S. D. et al. (2018) Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure, 11(7), e004962. (doi: 10.1161/CIRCHEARTFAILURE.118.004962) (PMID:29980595)

Ambrosy, A. P., Mentz, R. J., Fiuzat, M., Cleland, J. G.F. , Greene, S. J., O'Connor, C. M., Teerlink, J. R., Zannad, F. and Solomon, S. D. (2018) The role of angiotensin receptor–neprilysin inhibitors in cardiovascular disease—existing evidence, knowledge gaps, and future directions. European Journal of Heart Failure, 20(6), pp. 963-972. (doi: 10.1002/ejhf.1159) (PMID:29464817)

Dickstein, K. et al. (2018) CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how? European Journal of Heart Failure, 20(6), pp. 1039-1051. (doi: 10.1002/ejhf.1142) (PMID:29457358)

Sze, S., Pellicori, P. , Kazmi, S., Rigby, A., Cleland, J. G.F. , Wong, K. and Clark, A. L. (2018) Prevalence and prognostic significance of malnutrition using 3 scoring systems among outpatients with heart failure: a comparison with body mass index. JACC: Heart Failure, 6(6), pp. 476-486. (doi: 10.1016/j.jchf.2018.02.018) (PMID:29753673)

Zymliński, R. et al. (2018) Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion. European Journal of Heart Failure, 20(6), pp. 1011-1018. (doi: 10.1002/ejhf.1156) (PMID:29431284)

Rubio-Gracia, J. et al. (2018) Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. International Journal of Cardiology, 258, pp. 185-191. (doi: 10.1016/j.ijcard.2018.01.067) (PMID:29544928)

Beusekamp, J. C. et al. (2018) Potassium and the use of renin–angiotensin–aldosterone system inhibitors in heart failure with reduced ejection fraction. European Journal of Heart Failure, 20(5), pp. 923-930. (doi: 10.1002/ejhf.1079) (PMID:29359813)

Cosmi, F. et al. (2018) Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. European Journal of Heart Failure, 20(5), pp. 888-895. (doi: 10.1002/ejhf.1146) (PMID:29488676)

Ferrari, R. et al. (2018) Acute heart failure: lessons learned, roads ahead. European Journal of Heart Failure, 20(5), pp. 842-850. (doi: 10.1002/ejhf.1169) (PMID:29517124)

Metra, M. et al. (2018) Prognostic significance of creatinine increases during an acute heart failure admission in patients with and without residual congestion. Circulation: Heart Failure, 11(5), e004644. (doi: 10.1161/CIRCHEARTFAILURE.117.004644) (PMID:29748350)

Salvi, D. et al. (2018) An m-health system for education and motivation in cardiac rehabilitation: the experience of heartcycle guided exercise. Journal of Telemedicine and Telecare, 24(4), pp. 303-316. (doi: 10.1177/1357633X17697501) (PMID:28350282)

Ferreira, J. P. et al. (2018) Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. Heart, 104(7), pp. 606-613. (doi: 10.1136/heartjnl-2017-311750) (PMID:28798192)

Fröhlich, H. et al. (2018) Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study. European Heart Journal: Cardiovascular Pharmacotherapy, 4(2), pp. 82-92. (doi: 10.1093/ehjcvp/pvx013) (PMID:28475676)

Linde, C., Cleland, J. G.F. , Gold, M. R., Daubert, J. C., Tang, A. S.L., Young, J. B., Sherfesee, L. and Abraham, W. T. (2018) The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. European Journal of Heart Failure, 20(4), pp. 780-791. (doi: 10.1002/ejhf.1133) (PMID:29314424)

Sokoreli, I., Pauws, S. C., Steyerberg, E. W., de Vries, G.-J., Riistama, J. M., Tesanovic, A., Kazmi, S., Pellicori, P. , Cleland, J. G. and Clark, A. L. (2018) Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA-HF study. European Journal of Heart Failure, 20(4), pp. 689-696. (doi: 10.1002/ejhf.1112) (PMID:29314447)

Gho, J. M.I.H. et al. (2018) An electronic health records cohort study on heart failure following myocardial infarction in England: incidence and predictors. BMJ Open, 8(3), e018331. (doi: 10.1136/bmjopen-2017-018331) (PMID:29502083)

Stewart, R. A.H. et al. (2018) Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. Open Heart, 5(1), e000752. (doi: 10.1136/openhrt-2017-000752) (PMID:29531766) (PMCID:PMC5845417)

ter Maaten, J. M. et al. (2018) Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. International Journal of Cardiology, 253, pp. 84-90. (doi: 10.1016/j.ijcard.2017.10.010) (PMID:29306478)

Conrad, N. et al. (2018) Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet, 391(10120), pp. 10-16. (doi: 10.1016/S0140-6736(17)32520-5) (PMID:29174292) (PMCID:PMC5814791)

Cleland, J. G.F. (2018) Physicians Addicted to Prescribing Aspirin-a Disorder Of Cardiologists (PAPA-DOC) Syndrome: the headache of nonevidence-based medicine for ischemic heart disease? JACC: Heart Failure, 6(2), pp. 168-171. (doi: 10.1016/j.jchf.2017.11.014) (PMID:29413373)

Cotter, G. et al. (2018) Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe? European Journal of Heart Failure, 20(2), pp. 317-322. (doi: 10.1002/ejhf.889) (PMID:28871621)

Emmens, J. E. et al. (2018) Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure. European Journal of Heart Failure, 20(2), pp. 260-267. (doi: 10.1002/ejhf.1101) (PMID:29251807)

Nikolaidou, T., Pellicori, P. , Zhang, J., Kazmi, S., Goode, K. M., Cleland, J. G. and Clark, A. L. (2018) Prevalence, predictors, and prognostic implications of PR interval prolongation in patients with heart failure. Clinical Research in Cardiology, 107(2), pp. 108-119. (doi: 10.1007/s00392-017-1162-6) (PMID:28917011) (PMCID:PMC5790844)

Ouwerkerk, W. et al. (2018) Biomarker-guided versus guideline-based treatment of patients with heart failure: results from BIOSTAT-CHF. Journal of the American College of Cardiology, 71(4), pp. 386-398. (doi: 10.1016/j.jacc.2017.11.041) (PMID:29389354)

Cleland, J. G.F. , Flather, M. D., Altman, D. G. and Kotecha, D. (2018) Reply: an incomplete story. Journal of the American College of Cardiology, 71(1), p. 105. (doi: 10.1016/j.jacc.2017.10.078) (PMID:29301619)

Cleland, J. G.F. et al. (2018) Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal, 39(1), pp. 26-35. (doi: 10.1093/eurheartj/ehx564) (PMID:29040525)

Pellicori, P. , Urbinati, A., Zhang, J., Joseph, A. C., Costanzo, P., Lukaschuk, E., Capucci, A., Cleland, J. G.F. and Clark, A. L. (2018) Clinical and prognostic relationships of pulmonary artery to aorta diameter ratio in patients with heart failure: a cardiac magnetic resonance imaging study. Clinical Cardiology, 41(1), pp. 20-27. (doi: 10.1002/clc.22840) (PMID:29359813))

2017

Kaye, D. M., Silvestry, F. E., Gustafsson, F., Cleland, J. G. , van Veldhuisen, D. J., Ponikowski, P., Komtebedde, J., Nanayakkara, S., Burkhoff, D. and Shah, S. J. (2017) Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction. European Journal of Heart Failure, 19(12), pp. 1690-1697. (doi: 10.1002/ejhf.930) (PMID:29024227)

Bayes-Genis, A. et al. (2017) The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF subanalysis. Journal of the American College of Cardiology, 70(17), pp. 2128-2136. (doi: 10.1016/j.jacc.2017.08.057) (PMID:29050560)

Ferreira, J. P. et al. (2017) Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. European Journal of Heart Failure, 19(10), pp. 1284-1293. (doi: 10.1002/ejhf.900) (PMID:28580625)

Nassif, M. E. et al. (2017) Precision medicine for cardiac resynchronization: predicting quality of life benefits for individual patients-an analysis from 5 clinical trials. Circulation: Heart Failure, 10(10), e004111. (doi: 10.1161/CIRCHEARTFAILURE.117.004111) (PMID:29038172)

Sharma, A. et al. (2017) A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. European Journal of Heart Failure, 19(10), pp. 1310-1320. (doi: 10.1002/ejhf.912) (PMID:28639369)

Cleland, J. G.F. , Halliday, B. P. and Prasad, S. K. (2017) Selecting patients with nonischemic dilated cardiomyopathy for ICDs. Journal of the American College of Cardiology, 70(10), pp. 1228-1231. (doi: 10.1016/j.jacc.2017.07.748)

Cleland, J. G.F. (2017) Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably! European Journal of Heart Failure, 19(9), pp. 1086-1088. (doi: 10.1002/ejhf.697) (PMID:27943554)

Fröhlich, H. et al. (2017) Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. Clinical Research in Cardiology, 106(9), pp. 711-721. (doi: 10.1007/s00392-017-1115-0) (PMID:28434020)

Koudstaal, S. et al. (2017) Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people. European Journal of Heart Failure, 19(9), pp. 1119-1127. (doi: 10.1002/ejhf.709) (PMID:28008698) (PMCID:PMC5420446)

Cleland, J. G.F. (2017) What do cardiology and homeopathy have in common? : A belief in aspirin? JACC: Heart Failure, 5(8), pp. 611-614. (doi: 10.1016/j.jchf.2017.06.009) (PMID:28774397)

Gimpelewicz, C. et al. (2017) Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: a subgroup analysis from the RELAX-AHF trial. American Heart Journal, 190, pp. 113-122. (doi: 10.1016/j.ahj.2017.05.012)

Linde, C., Abraham, W. T., Gold, M. R., Daubert, C., Tang, A. S.L., Young, J. B., Sherfesee, L., Hudnall, H., Fagan, D. H. and Cleland, J. G. (2017) Predictors of short-term clinical response to cardiac resynchronization therapy. European Journal of Heart Failure, 19(8), pp. 1056-1063. (doi: 10.1002/ejhf.795) (PMID:28295869)

Halliday, B. P., Cleland, J. G.F. , Goldberger, J. J. and Prasad, S. K. (2017) Personalizing sudden death risk stratification in dilated cardiomyopathy: past, present and future. Circulation, 136(2), pp. 215-231. (doi: 10.1161/CIRCULATIONAHA.116.027134) (PMID:28696268)

Damman, K. et al. (2017) Plasma neutrophil gelatinase-associated lipocalin and predicting clinically relevant worsening renal function in acute heart failure. International Journal of Molecular Sciences, 18(7), 1470. (doi: 10.3390/ijms18071470) (PMID:28698481)

Shen, L. et al. (2017) Declining risk of sudden death in heart failure. New England Journal of Medicine, 377(1), pp. 41-51. (doi: 10.1056/NEJMoa1609758) (PMID:28679089)

Fröhlich, H. et al. (2017) Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure. International Journal of Cardiology, 238, pp. 97-104. (doi: 10.1016/j.ijcard.2017.03.028) (PMID:28342630)

Cleland, J. G.F. , Pellicori, P. , Clark, A. L. and Petrie, M. C. (2017) Time to take the failure out of heart failure: the importance of optimism. JACC: Heart Failure, 5(7), pp. 538-540. (doi: 10.1016/j.jchf.2017.04.003) (PMID:28624485)

Pellicori, P. , Clark, A. L., Kallvikbacka-Bennett, A., Zhang, J., Urbinati, A., Monzo, L., Dierckx, R., Anker, S. D. and Cleland, J. G.F. (2017) Non-invasive measurement of right atrial pressure by near-infrared spectroscopy: preliminary experience. A report from the SICA-HF study. European Journal of Heart Failure, 19(7), pp. 883-892. (doi: 10.1002/ejhf.825) (PMID:28387033)

Tromp, J. et al. (2017) Biomarker profiles of acute heart failure patients with a mid-range ejection fraction. JACC: Heart Failure, 5(7), pp. 507-517. (doi: 10.1016/j.jchf.2017.04.007) (PMID:28624483)

Ouwerkerk, W. et al. (2017) Determinants and clinical outcome of uptitration of ACE-inhibitor and beta-blocker in patients with heart failure: a prospective European study. European Heart Journal, 38(24), pp. 1883-1890. (doi: 10.1093/eurheartj/ehx026) (PMID:28329163)

Kotecha, D. et al. (2017) Heart rate, heart rhythm and prognostic benefits of beta-blockers in heart failure: individual patient-data meta-analysis. Journal of the American College of Cardiology, 69(24), pp. 2885-2896. (doi: 10.1016/j.jacc.2017.04.001) (PMID:28467883)

Cleland, J. G.F. et al. (2017) Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). European Journal of Heart Failure, 19(6), pp. 739-747. (doi: 10.1002/ejhf.786) (PMID:28296139)

Demissei, B. G. et al. (2017) Plasma biomarkers to predict or rule out early post-discharge events in patients discharged after an acute heart failure hospital admission. European Journal of Heart Failure, 19(6), pp. 728-738. (doi: 10.1002/ejhf.766) (PMID:28251755)

Liu, L. C.Y. et al. (2017) Identifying subpopulations with distinct response to treatment using plasma biomarkers in acute heart failure: results from the PROTECT trial. Cardiovascular Drugs and Therapy, 31(3), pp. 281-293. (doi: 10.1007/s10557-017-6726-1) (PMID:28656542) (PMCID:PMC5550531)

McCoy, J. et al. (2017) Pathophysiology of exercise intolerance in chronic diseases: the role of diminished cardiac performance in mitochondrial and heart failure patients. Open Heart, 4(2), e000632. (doi: 10.1136/openhrt-2017-000632) (PMID:28878952) (PMCID:PMC5574430)

Pellicori, P. , Urbinati, A., Shah, P., MacNamara, A., Kazmi, S., Dierckx, R., Zhang, J., Cleland, J. G.F. and Clark, A. L. (2017) What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? European Journal of Heart Failure, 19(6), pp. 768-778. (doi: 10.1002/ejhf.788) (PMID:28244205)

Ritchie, J. et al. (2017) Effect of renal artery revascularization upon cardiac structure and function in atherosclerotic renal artery stenosis: cardiac magnetic resonance sub-study of the ASTRAL trial. Nephrology Dialysis Transplantation, 32(6), pp. 1006-1013. (doi: 10.1093/ndt/gfw107) (PMID:27257278)

Halliday, B. P. et al. (2017) Association between mid-wall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation, 135(22), pp. 2106-2115. (doi: 10.1161/CIRCULATIONAHA.116.026910) (PMID:28351901)

Jacobs, L. et al. (2017) Risk for incident heart failure: a subject-level meta-analysis from the Heart “OMics” in AGEing (HOMAGE) study. Journal of the American Heart Association, 6(5), e005231. (doi: 10.1161/JAHA.116.005231) (PMID:28465299)

Voors, A. A. et al. (2017) Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. European Journal of Heart Failure, 19(5), pp. 627-634. (doi: 10.1002/ejhf.785) (PMID:28247565)

Zakeri, R. et al. (2017) The burden of proof: the current state of atrial fibrillation prevention and treatment trials. Heart Rhythm, 14(5), pp. 763-782. (doi: 10.1016/j.hrthm.2017.01.032) (PMID:28161513)

Zhang, J., Wong, K. Y.-K., Clark, A. L. and Cleland, J. G.F. (2017) Exploring the relation between changes in NT-proBNP and renal function in patients with suspected heart failure using structural equation modelling. International Journal of Cardiology, 233, pp. 67-72. (doi: 10.1016/j.ijcard.2017.01.127) (PMID:28169056)

McDiarmid, A. K., Pellicori, P. , Cleland, J. G.F. and Plein, S. (2017) Taxonomy of segmental myocardial systolic dysfunction. European Heart Journal, 38(13), pp. 942-954. (doi: 10.1093/eurheartj/ehw140) (PMID:27147609) (PMCID:PMC5381597)

Brown, D. A. et al. (2017) Expert consensus document: mitochondrial function as a therapeutic target in heart failure. Nature Reviews Cardiology, 14, pp. 238-250. (doi: 10.1038/nrcardio.2016.203) (PMID:28004807)

Cleland, J. G.F. and Mueller, C. (2017) What can we learn from SOCRATES: more questions than answers? European Heart Journal, 38(15), pp. 1128-1131. (doi: 10.1093/eurheartj/ehw561) (PMID:28204466)

Filippatos, G. S. et al. (2017) Independent academic data monitoring committees for clinical trials in cardiovascular and cardiometabolic diseases. European Journal of Heart Failure, 19(4), pp. 449-456. (doi: 10.1002/ejhf.761) (PMID:28271595)

Nymo, S. H. et al. (2017) Limited added value of circulating inflammatory biomarkers in chronic heart failure. JACC: Heart Failure, 5(4), pp. 256-264. (doi: 10.1016/j.jchf.2017.01.008) (PMID:28359413)

Skobel, E. et al. (2017) Internet-based training of coronary artery patients: the Heart Cycle Trial. Heart and Vessels, 32(4), pp. 408-418. (doi: 10.1007/s00380-016-0897-8) (PMID:27730298)

Rao, M. P. et al. (2017) Sudden cardiac death in patients with ischemic heart failure undergoing coronary artery bypass grafting results from the STICH randomized clinical trial (Surgical Treatment for Ischemic Heart Failure). Circulation, 135, pp. 1136-1144. (doi: 10.1161/CIRCULATIONAHA.116.026075) (PMID:28154006)

Dovancescu, S., Pellicori, P. , Mabote, T., Torabi, A., Clark, A. L. and Cleland, J. G.F. (2017) The effects of short-term omission of daily medication on the pathophysiology of heart failure. European Journal of Heart Failure, (doi: 10.1002/ejhf.748) (PMID:28295907)

Dierckx, R., Inglis, S. C., Clark, R. A., Prieto-Merino, D. and Cleland, J. G.F. (2017) Telemedicine in heart failure: new insights from the Cochrane meta-analyses. European Journal of Heart Failure, 19(3), pp. 304-306. (doi: 10.1002/ejhf.759) (PMID:28251777)

Masters, J., Morton, G., Anton, I., Szymanski, J., Greenwood, E., Grogono, J., Flett, A. S., Cleland, J. G.F. and Cowburn, P. J. (2017) Specialist intervention is associated with improved patient outcomes in patients with decompensated heart failure: evaluation of the impact of a multidisciplinary inpatient heart failure team. Open Heart, 4(1), e000547. (doi: 10.1136/openhrt-2016-000547) (PMID:28409010) (PMCID:PMC5384462)

Matsue, Y. et al. (2017) Clinical correlates and prognostic value of proenkephalin in acute and chronic heart failure. Journal of Cardiac Failure, 23(3), pp. 231-239. (doi: 10.1016/j.cardfail.2016.09.007) (PMID:27663098)

Matsue, Y. et al. (2017) Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. Heart, 103(6), pp. 407-413. (doi: 10.1136/heartjnl-2016-310112) (PMID:27658757)

Emdin, C. A. et al. (2017) Referral for specialist follow-up and its association with post-discharge mortality among patients with systolic heart failure (from the National Heart Failure Audit for England and Wales). American Journal of Cardiology, 119(3), pp. 440-444. (doi: 10.1016/j.amjcard.2016.10.021) (PMID:27884420) (PMCID:PMC5282396)

Gastelurrutia, P., Lupón, J., Domingo, M., Stut, W., Dovancescu, S., Cleland, J. , Frankenstein, L. and Bayes-Genis, A. (2017) Potential role for clinical calibration to increase engagement with and application of home telemonitoring: a report from the HeartCycle programme. ESC Heart Failure, 4(1), pp. 66-70. (doi: 10.1002/ehf2.12104) (PMID:28217314) (PMCID:PMC5292630)

Zhang, J., Dierckx, R., Mohee, K., Clark, A. L. and Cleland, J. G.F. (2017) Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta-analysis. ESC Heart Failure, 4(1), pp. 40-45. (doi: 10.1002/ehf2.12112) (PMID:28217311) (PMCID:PMC5292634)

Streng, K. W. et al. (2017) Associations of body mass index with laboratory and biomarkers in patients with acute heart failure. Circulation: Heart Failure, 10(1), e003350. (doi: 10.1161/CIRCHEARTFAILURE.116.003350) (PMID:28069685)

Tromp, J. et al. (2017) Serum potassium levels and outcome in acute heart failure (data from the PROTECT and COACH trials). American Journal of Cardiology, 119(2), pp. 290-296. (doi: 10.1016/j.amjcard.2016.09.038) (PMID:27823598)

Arain, F., Gullestad, L., Nymo, S., Kjekshus, J., Cleland, J. G.F. , Michelsen, A., McMurray, J. J.V. , Wikstrand, J., Aukrust, P. and Ueland, T. (2017) Low YKL-40 in Chronic Heart Failure may predict beneficial effects of statins: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Biomarkers, 22, pp. 261-267. (doi: 10.1080/1354750X.2016.1204003) (PMID:27325138)

2016

Torabi, A. et al. (2016) Influence of case definition on incidence and outcome of acute coronary syndromes. Open Heart, 3(2), e000487. (doi: 10.1136/openhrt-2016-000487)

Teerlink, J. R. et al. (2016) Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet, 388(10062), pp. 2895-2903. (doi: 10.1016/S0140-6736(16)32049-9)

Vegter, E. L. et al. (2016) Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. International Journal of Cardiology, 224, pp. 231-239. (doi: 10.1016/j.ijcard.2016.09.010) (PMID:27661412)

Pellicori, P. , Cleland, J. G.F. , Zhang, J., Kallvikbacka-Bennett, A., Urbinati, A., Shah, P., Kazmi, S. and Clark, A. L. (2016) Cardiac dysfunction, congestion and loop diuretics: their relationship to prognosis in heart failure. Cardiovascular Drugs and Therapy, 30(6), pp. 599-609. (doi: 10.1007/s10557-016-6697-7) (PMID:27819111)

Inglis, S. C., Clark, R. A., Dierckx, R., Prieto-Merino, D. and Cleland, J. G.F. (2016) Structured telephone support or non-invasive telemonitoring for patients with heart failure. Heart, 103(4), pp. 255-257. (doi: 10.1136/heartjnl-2015-309191) (PMID:27864319)

Demissei, B. G. et al. (2016) Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure — Post-hoc analysis of the PROTECT trial. International Journal of Cardiology, 223, pp. 967-975. (doi: 10.1016/j.ijcard.2016.08.271) (PMID:27589047)

Ferreira, J. P. et al. (2016) Renal function estimation and Cockroft–Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: the Heart ‘OMics’ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Medicine, 14, 181. (doi: 10.1186/s12916-016-0731-2) (PMID:27829460) (PMCID:PMC5103492)

Bekfani, T. et al. (2016) Sarcopenia in patients with heart failure with preserved ejection fraction: impact on muscle strength, exercise capacity and quality of life. International Journal of Cardiology, 222, pp. 41-46. (doi: 10.1016/j.ijcard.2016.07.135) (PMID:27454614)

Tromp, J. et al. (2016) Acute heart failure in the young: clinical characteristics and biomarker profiles. International Journal of Cardiology, 221, pp. 1067-1072. (doi: 10.1016/j.ijcard.2016.06.339) (PMID:27448534)

Sokoreli, I. et al. (2016) Depression as an independent prognostic factor for all-cause mortality after a hospital admission for worsening heart failure. International Journal of Cardiology, 220, pp. 202-207. (doi: 10.1016/j.ijcard.2016.06.068) (PMID:27389442)

Cleland, J. G.F. and Pellicori, P. (2016) PARADIGM-HF: does dose matter? European Journal of Heart Failure, 18(10), pp. 1235-1237. (doi: 10.1002/ejhf.634) (PMID:27704710)

Cotter, G. et al. (2016) Predictors and associations with outcomes of length of hospital stay in patients with acute heart failure: results from VERITAS. Journal of Cardiac Failure, 22(10), pp. 815-822. (doi: 10.1016/j.cardfail.2015.12.017) (PMID:26721775)

ter Maaten, J. M. et al. (2016) Hypochloremia, diuretic resistance, and outcome in patients with acute heart failure. Circulation: Heart Failure, 9(8), e003109. (doi: 10.1161/CIRCHEARTFAILURE.116.003109) (PMID:27507112)

Bhattacharyya, S., Mittal, T., Abayalingam, M., Kabir, T., Dalby, M., Cleland, J. G.F. , Baltabaeva, A. and Rahman Haley, S. (2016) Classification of aortic stenosis by flow and gradient patterns provides insights into the pathophysiology of disease. Angiology, 67(7), pp. 664-669. (doi: 10.1177/0003319715611804) (PMID:26475710)

Cleland, J. G.F. , Zhang, J., Pellicori, P. , Dicken, B., Dierckx, R., Shoaib, A., Wong, K., Rigby, A., Goode, K. and Clark, A. L. (2016) Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure. JAMA Cardiology, 1(5), pp. 539-547. (doi: 10.1001/jamacardio.2016.1161) (PMID:27439011)

Davison, B. A. et al. (2016) Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. European Journal of Heart Failure, 18(8), pp. 1041-1050. (doi: 10.1002/ejhf.540) (PMID:27114058)

Fröhlich, H. et al. (2016) Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease. American Heart Journal, 178, pp. 28-36. (doi: 10.1016/j.ahj.2016.03.024) (PMID:27502849)

Ponikowski, P. et al. (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 18(8), pp. 891-975. (doi: 10.1002/ejhf.592) (PMID:27207191)

Biegus, J. et al. (2016) Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. European Journal of Heart Failure, 18(7), pp. 830-839. (doi: 10.1002/ejhf.532) (PMID:27170455)

Feldman, T. et al. (2016) Transcatheter interatrial shunt device for the treatment of heart failure: rationale and design of the randomized trial to REDUCE elevated left atrial pressure in heart failure (REDUCE LAP-HF I). Circulation: Heart Failure, 9(7), e003025. (doi: 10.1161/CIRCHEARTFAILURE.116.003025) (PMID:27330010)

Emmens, J. E. et al. (2016) Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. European Journal of Heart Failure, 18(6), pp. 641-649. (doi: 10.1002/ejhf.426) (PMID:26511274)

ter Maaten, J. M. et al. (2016) Combining diuretic response and hemoconcentration to predict rehospitalization after admission for acute heart failure. Circulation: Heart Failure, 9(6), e002845. (doi: 10.1161/CIRCHEARTFAILURE.115.002845) (PMID:27266853)

Voors, A. A. et al. (2016) A systems BIOlogy Study to TAilored treatment in chronic heart failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. European Journal of Heart Failure, 18(6), pp. 716-726. (doi: 10.1002/ejhf.531) (PMID:27126231)

Pellicori, P. , Goode, K. M., Nicholls, R., Ahmed, D., Clark, A. L. and Cleland, J. G.F. (2016) Regional circulatory distribution of novel cardiac bio-markers and their relationships with haemodynamic measurements. International Journal of Cardiology, 210, pp. 149-155. (doi: 10.1016/j.ijcard.2016.02.081) (PMID:26946041)

Gheorghiade, M. et al. (2016) Developing new treatments for heart failure: focus on the heart. Circulation: Heart Failure, 9(5), e002727. (doi: 10.1161/CIRCHEARTFAILURE.115.002727) (PMID:27166246)

Pellicori, P. and Cleland, J.G.F. (2016) New ways to visualize and combat congestion in heart failure = Nuevos modos de visualizar y combatir la congestión en la insuficiencia cardiaca. Revista Clínica Española, 216(4), pp. 202-204. (doi: 10.1016/j.rce.2016.03.007) (PMID:27129360)

Shoaib, A. et al. (2016) Is the diagnostic coding position of acute heart failure related to mortality? A report from the Euro Heart Failure Survey-1. European Journal of Heart Failure, 18(5), pp. 556-563. (doi: 10.1002/ejhf.505) (PMID:26991150)

Kotecha, D. et al. (2016) Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. British Medical Journal, 353, i1855. (doi: 10.1136/bmj.i1855) (PMID:27098105) (PMCID:PMC4849174)

Ovchinnikova, E. S. et al. (2016) Signature of circulating microRNAs in patients with acute heart failure. European Journal of Heart Failure, 18(4), pp. 414-423. (doi: 10.1002/ejhf.332) (PMID:26345695)

Teerlink, J. R. et al. (2016) Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure. Journal of the American College of Cardiology, 67(12), pp. 1444-1455. (doi: 10.1016/j.jacc.2016.01.031) (PMID:27012405)

Hasenfuß, G. et al. (2016) A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet, 387(10025), pp. 1298-1304. (doi: 10.1016/S0140-6736(16)00704-2) (PMID:27025436)

Damman, K., Kjekshus, J., Wikstrand, J., Cleland, J. G.F. , Komajda, M., Wedel, H., Waagstein, F. and McMurray, J. J.V. (2016) Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 18(3), pp. 328-336. (doi: 10.1002/ejhf.462) (PMID:26693947)

Demissei, B. G. et al. (2016) Optimizing clinical use of biomarkers in high-risk acute heart failure patients. European Journal of Heart Failure, 18(3), pp. 269-280. (doi: 10.1002/ejhf.443) (PMID:26634889)

Cuba Gyllensten, I., Bonomi, A. G., Goode, K. M., Reiter, H., Habetha, J., Amft, O. and Cleland, J. G.F. (2016) Early indication of decompensated heart failure in patients on home-telemonitoring: a comparison of prediction algorithms based on daily weight and noninvasive transthoracic bio-impedance. JMIR Medical Informatics, 4(1), e3. (doi: 10.2196/medinform.4842) (PMID:26892844) (PMCID:PMC4777885)

Demissei, B. G. et al. (2016) Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. International Journal of Cardiology, 204, pp. 164-171. (doi: 10.1016/j.ijcard.2015.11.141) (PMID:26666342)

Bhandari, S., Ives, N., Brettell, E. A., Valente, M., Cockwell, P., Topham, P. S., Cleland, J. G.F. , Khwaja, A. and El Nahas, M. (2016) Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. Nephrology Dialysis Transplantation, 31(2), pp. 255-261. (doi: 10.1093/ndt/gfv346) (PMID:26429974) (PMCID:PMC4725389)

ter Maaten, J. M. et al. (2016) A combined clinical and biomarker approach to predict diuretic response in acute heart failure. Clinical Research in Cardiology, 105(2), pp. 145-153. (doi: 10.1007/s00392-015-0896-2) (PMID:26280875) (PMCID:PMC4735256)

Bruno, N. et al. (2016) MicroRNAs relate to early worsening of renal function in patients with acute heart failure. International Journal of Cardiology, 203, pp. 564-569. (doi: 10.1016/j.ijcard.2015.10.217) (PMID:26569364)

Zhang, J., Hobkirk, J., Carroll, S., Pellicori, P. , Clark, A. L. and Cleland, J. G.F. (2016) Exploring quality of life in patients with and without heart failure. International Journal of Cardiology, 202, pp. 676-684. (doi: 10.1016/j.ijcard.2015.09.076) (PMID:26453816)

Cowie, M. R., Bax, J., Bruining, N., Cleland, J. G.F. , Koehler, F., Malik, M., Pinto, F., van der Velde, E. and Vardas, P. (2016) e-Health: a position statement of the European Society of Cardiology. European Heart Journal, 37(1), pp. 63-66. (doi: 10.1093/eurheartj/ehv416) (PMID:26303835)

Emdin, C. A. et al. (2016) Variation in hospital performance for heart failure management in the National Heart Failure Audit for England and Wales. Heart, 103(1), pp. 55-62. (doi: 10.1136/heartjnl-2016-309706) (PMID:27530132)

Ponikowski, P. et al. (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37(27), pp. 2129-2200. (doi: 10.1093/eurheartj/ehw128) (PMID:27206819)

2015

Cleland, J. G.F. and Mareev, Y. (2015) CRT for heart failure and ESRD: more trials or more thought needed? Journal of the American College of Cardiology, 66(23), pp. 2630-2632. (doi: 10.1016/j.jacc.2015.10.022) (PMID:26670063)

Jolicœur, E. M. et al. (2015) Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction. Journal of the American College of Cardiology, 66(19), pp. 2092-2100. (doi: 10.1016/j.jacc.2015.08.882) (PMID:26541919)

Pellicori, P. , Joseph, A. C., Zhang, J., Lukaschuk, E., Sherwi, N., Bourantas, C. V., Loh, H., Clark, A. L. and Cleland, J. G.F. (2015) The relationship of QRS morphology with cardiac structure and function in patients with heart failure. Clinical Research in Cardiology, 104(11), pp. 935-945. (doi: 10.1007/s00392-015-0861-0) (PMID:25903113)

Inglis, S. C., Clark, R. A., Dierckx, R., Prieto-Merino, D. and Cleland, J. G.F. (2015) Structured telephone support or non-invasive telemonitoring for patients with heart failure. Cochrane Database of Systematic Reviews, 2015(10), CD007228. (doi: 10.1002/14651858.CD007228.pub3) (PMID:26517969)

Farag, M., Mabote, T., Shoaib, A., Zhang, J., Nabhan, A. F., Clark, A. L. and Cleland, J. G. (2015) Hydralazine and nitrates alone or combined for the management of chronic heart failure: a systematic review. International Journal of Cardiology, 196, pp. 61-69. (doi: 10.1016/j.ijcard.2015.05.160) (PMID:26073215)

Mareev, Y. and Cleland, J. G.F. (2015) Should β-blockers be used in patients with heart failure and atrial fibrillation? Clinical Therapeutics, 37(10), pp. 2215-2224. (doi: 10.1016/j.clinthera.2015.08.017) (PMID:26391145)

Butcher, C., Mareev, Y., Markides, V., Mason, M., Wong, T. and Cleland, J.G.F. (2015) Cardiac resynchronization therapy update: evolving indications, expanding benefit? Current Cardiology Reports, 17(10), 90. (doi: 10.1007/s11886-015-0641-5) (PMID:26298308)

Frankenstein, L., Fröhlich, H. and Cleland, J. G.F. (2015) Multidisciplinary approach for patients hospitalized with heart failure. Revista Española de Cardiología (English Edition), 68(10), pp. 885-891. (doi: 10.1016/j.rec.2015.05.008) (PMID:26409892)

Shadman, R. et al. (2015) A novel method to predict the proportional risk of sudden cardiac death in heart failure: derivation of the Seattle Proportional Risk Model. Heart Rhythm, 12(10), pp. 2069-2077. (doi: 10.1016/j.hrthm.2015.06.039) (PMID:26142301)

Cleland, J. G.F. and Freemantle, N. (2015) QRS morphology as a predictor of the response to cardiac resynchronisation therapy: fact or fashion? Heart, 101(18), pp. 1441-1443. (doi: 10.1136/heartjnl-2015-307553) (PMID:26187602)

Damy, T. et al. (2015) Development of a human model for the study of effects of hypoxia, exercise, and sildenafil on cardiac and vascular function in chronic heart failure. Journal of Cardiovascular Pharmacology, 66(3), pp. 229-238. (doi: 10.1097/FJC.0000000000000262) (PMID:25874853)

Dierckx, R., Cleland, J. G.F. , Pellicori, P. , Zhang, J., Goode, K., Putzu, P., Boyalla, V. and Clark, A. L. (2015) If home telemonitoring reduces mortality in heart failure, is this just due to better guideline-based treatment? Journal of Telemedicine and Telecare, 21(6), pp. 331-339. (doi: 10.1177/1357633X15574947) (PMID:25766855)

Stut, W., Deighan, C., Cleland, J. G. and Jaarsma, T. (2015) Adherence to self-care in patients with heart failure in the HeartCycle study. Patient Preference and Adherence, 9, pp. 1195-1206. (doi: 10.2147/PPA.S88482) (PMID:26316725) (PMCID:PMC4548736)

Askevold, E. T., Gullestad, L., Nymo, S., Kjekshus, J., Yndestad, A., Latini, R., Cleland, J. G.F. , McMurray, J. J.V. , Aukrust, P. and Ueland, T. (2015) Secreted frizzled related protein 3 in chronic heart failure: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). PLoS ONE, 10(8), e0133970. (doi: 10.1371/journal.pone.0133970) (PMID:26288364) (PMCID:PMC4545831)

Cleland, J. G.F. , Mareev, Y. and Linde, C. (2015) Reflections on EchoCRT: sound guidance on QRS duration and morphology for CRT? European Heart Journal, 36(30), pp. 1948-1951. (doi: 10.1093/eurheartj/ehv264) (PMID:26180135)

Raphael, C. E., Finegold, J. A., Barron, A. J., Whinnett, Z. I., Mayet, J., Linde, C., Cleland, J. G.F. , Levy, W. C. and Francis, D. P. (2015) The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most? European Heart Journal, 36(26), pp. 1676-1688. (doi: 10.1093/eurheartj/ehv102) (PMID:25908776)

Ferrari, R., Böhm, M., Cleland, J. G.F. , Paulus, W. J.S., Pieske, B., Rapezzi, C. and Tavazzi, L. (2015) Heart failure with preserved ejection fraction: uncertainties and dilemmas. European Journal of Heart Failure, 17(7), pp. 665-671. (doi: 10.1002/ejhf.304) (PMID:26079097)

Mentz, R. J. et al. (2015) Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. European Journal of Heart Failure, 17(7), pp. 697-706. (doi: 10.1002/ejhf.308) (PMID:26083764)

Pellicori, P. , Kallvikbacka-Bennett, A., Dierckx, R., Zhang, J., Putzu, P., Cuthbert, J., Boyalla, V., Shoaib, A., Clark, A. L. and Cleland, J. G.F. (2015) Prognostic significance of ultrasound-assessed jugular vein distensibility in heart failure. Heart, 101(14), pp. 1149-1158. (doi: 10.1136/heartjnl-2015-307558) (PMID:26006717)

Zannad, F., Greenberg, B., Cleland, J. G.F. , Gheorghiade, M., van Veldhuisen, D. J., Mehra, M. R., Anker, S. D., Byra, W. M., Fu, M. and Mills, R. M. (2015) Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial. European Journal of Heart Failure, 17(7), pp. 735-742. (doi: 10.1002/ejhf.266) (PMID:25919061) (PMCID:PMC5029775)

Inglis, S. C., Conway, A., Cleland, J. G.F. and Clark, R. A. (2015) Is age a factor in the success or failure of remote monitoring in heart failure? Telemonitoring and structured telephone support in elderly heart failure patients. European Journal of Cardiovascular Nursing, 14(3), pp. 248-255. (doi: 10.1177/1474515114530611) (PMID:24681423)

Kristensen, S. L., Jhund, P. S. , Køber, L., McKelvie, R. S., Zile, M. R., Anand, I. S., Komajda, M., Cleland, J. G.F. , Carson, P. E. and McMurray, J. J.V. (2015) Relative importance of history of heart failure hospitalization and N-terminal pro–B-type natriuretic peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 3(6), pp. 478-486. (doi: 10.1016/j.jchf.2015.01.014) (PMID:26046842)

Costanzo, P., Cleland, J. G.F. , Pellicori, P. , Clark, A. L., Hepburn, D., Kilpatrick, E. S., Perrone-Filardi, P., Zhang, J. and Atkin, S. L. (2015) The obesity paradox in type 2 diabetes mellitus: relationship of body mass index to prognosis: a cohort study. Annals of Internal Medicine, 162(9), pp. 610-618. (doi: 10.7326/M14-1551) (PMID:25938991)

Davison, B. A. et al. (2015) Worsening heart failure following admission for acute heart failure: a pooled analysis of the PROTECT and RELAX-AHF studies. JACC: Heart Failure, 3(5), pp. 395-403. (doi: 10.1016/j.jchf.2015.01.007) (PMID:25951761)

Filippatos, G. et al. (2015) International REgistry to assess medical practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. European Journal of Heart Failure, 17(5), pp. 527-533. (doi: 10.1002/ejhf.262) (PMID:25754836) (PMCID:PMC5024037)

Cleland, J. G.F. and Butcher, C. (2015) When is it appropriate to withdraw cardiac resynchronization therapy? Guesses and evidence. JACC: Heart Failure, 3(4), pp. 337-339. (doi: 10.1016/j.jchf.2015.01.003) (PMID:25770401)

Pellicori, P. , Zhang, J., Lukaschuk, E., Joseph, A. C., Bourantas, C. V., Loh, H., Bragadeesh, T., Clark, A. L. and Cleland, J. G.F. (2015) Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value. European Heart Journal, 36(12), pp. 733-742. (doi: 10.1093/eurheartj/ehu405) (PMID:25336215)

Jankowska, E. A. et al. (2015) Bone marrow iron depletion is common in patients with coronary artery disease. International Journal of Cardiology, 182, pp. 517-522. (doi: 10.1016/j.ijcard.2014.10.006) (PMID:25661858)

Dierckx, R., Cleland, J. G.F. , Parsons, S., Putzu, P., Pellicori, P. , Dicken, B., Boyalla, V. and Clark, A. L. (2015) Prescribing patterns to optimize heart rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period. JACC: Heart Failure, 3(3), pp. 224-230. (doi: 10.1016/j.jchf.2014.11.003) (PMID:25650369)

Khand, A. U., Chew, P. G., Douglas, H., Jones, J., Jan, A. and Cleland, J.G.F. (2015) The effect of carvedilol on b-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation. Cardiology, 130(3), pp. 153-158. (doi: 10.1159/000368746) (PMID:25660493)

Metra, M. et al. (2015) Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study. Journal of Cardiac Failure, 21(3), pp. 179-88. (doi: 10.1016/j.cardfail.2014.12.012) (PMID:25573829)

Pellicori, P. and Cleland, J. G.F. (2015) Is the epidemic of heart disease really over or just evolving? American Journal of Medicine, 128(3), e17. (doi: 10.1016/j.amjmed.2014.09.018) (PMID:25707889)

Pellicori, P. and Cleland, J. G.F. (2015) Update on management of heart failure with preserved ejection fraction. Current Opinion in Cardiology, 30(2), pp. 173-178. (doi: 10.1097/HCO.0000000000000152) (PMID:25603033)

Kristensen, S. L. et al. (2015) Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure, 17(2), pp. 169-176. (doi: 10.1002/ejhf.211) (PMID:25756844)

Dickstein, K. et al. (2015) European cardiac resynchronization therapy survey II: rationale and design. Europace, 17(1), pp. 137-141. (doi: 10.1093/europace/euu312) (PMID:25414481)

Dierckx, R., Pellicori, P. , Cleland, J.G.F. and Clark, A.L. (2015) Telemonitoring in heart failure: Big Brother watching over you. Heart Failure Reviews, 20(1), pp. 107-116. (doi: 10.1007/s10741-014-9449-4) (PMID:24972644)

Metra, M. et al. (2015) Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. European Journal of Heart Failure, 17(1), pp. 109-118. (doi: 10.1002/ejhf.207) (PMID:25431336)

2014

Badar, A. A. et al. (2014) Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal, 35(48), pp. 3426-3433. (doi: 10.1093/eurheartj/ehu342)

Kotecha, D. et al. (2014) Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet, 384(9961), pp. 2235-2243. (doi: 10.1016/S0140-6736(14)61373-8) (PMID:25193873)

Stut, W., Deighan, C., Armitage, W., Clark, M., Cleland, J. G. and Jaarsma, T. (2014) Design and usage of the HeartCycle education and coaching program for patients with heart failure. JMIR Research Protocols, 3(4), e72. (doi: 10.2196/resprot.3411) (PMID:25499976) (PMCID:PMC4275507)

Cotter, G. et al. (2014) Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. European Journal of Heart Failure, 16(12), pp. 1362-1371. (doi: 10.1002/ejhf.186) (PMID:25371147)

Pellicori, P. and Cleland, J. G.F. (2014) Heart failure with preserved ejection fraction. Clinical Medicine, 14(S6), s22-s28. (doi: 10.7861/clinmedicine.14-6-s22) (PMID:25468914)

Shoaib, A. et al. (2014) Breathlessness at rest is not the dominant presentation of patients admitted with heart failure. European Journal of Heart Failure, 16(12), pp. 1283-1291. (doi: 10.1002/ejhf.153) (PMID:25452165)

Ahmad, T. et al. (2014) Charting a roadmap for heart failure biomarker studies. JACC: Heart Failure, 2(5), pp. 477-488. (doi: 10.1016/j.jchf.2014.02.005) (PMID:24929535) (PMCID:PMC4194170)

Cleland, J. G.F. , Hutchinson, K., Pellicori, P. and Clark, A. (2014) Lipid-modifying treatments for heart failure: is their use justified? Heart Failure Clinics, 10(4), pp. 621-634. (doi: 10.1016/j.hfc.2014.07.006) (PMID:25217437)

Parsons, S., Clark, A. L. and Cleland, J. G.F. (2014) The remarkable effect of ivabradine in two adolescents with dilated cardiomyopathy. Clinical Research in Cardiology, 103(10), pp. 847-849. (doi: 10.1007/s00392-014-0731-1) (PMID:24920068)

Jankowska, E. A. et al. (2014) Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. European Heart Journal, 35(36), pp. 2468-2476. (doi: 10.1093/eurheartj/ehu235) (PMID:24927731)

Dicken, B. and Cleland, J. G.F. (2014) Is the way to a man’s heart through his stomach? Intestinal blood flow, gut permeability, and heart failure. Journal of the American College of Cardiology, 64(11), pp. 1103-1105. (doi: 10.1016/j.jacc.2014.06.1180)

Hutchinson, K., Pellicori, P., Dierckx, R., Cleland, J. G.F. and Clark, A. L. (2014) Remote telemonitoring for patients with heart failure: might monitoring pulmonary artery pressure become routine? Expert Review of Cardiovascular Therapy, 12(8), pp. 1025-1033. (doi: 10.1586/14779072.2014.935340) (PMID:24984847)

Mabote, T., Wong, K. and Cleland, J. G.F. (2014) The utility of novel non-invasive technologies for remote hemodynamic monitoring in chronic heart failure. Expert Review of Cardiovascular Therapy, 12(8), pp. 923-928. (doi: 10.1586/14779072.2014.935339) (PMID:25026973)

Stewart, R. A.H. et al. (2014) Exercise capacity and mortality in patients with ischemic left ventricular dysfunction randomized to coronary artery bypass graft surgery or medical therapy: an analysis from the STICH trial (Surgical Treatment for Ischemic Heart Failure). JACC: Heart Failure, 2(4), pp. 335-343. (doi: 10.1016/j.jchf.2014.02.009) (PMID:25023813) (PMCID:PMC4127151)

Cleland, J. G.F. , Pellicori, P. and Dierckx, R. (2014) Clinical trials in patients with heart failure and preserved left ventricular ejection fraction. Heart Failure Clinics, 10(3), pp. 511-523. (doi: 10.1016/j.hfc.2014.04.011) (PMID:24975913)

Cullington, D., Goode, K. M., Zhang, J., Cleland, J. G.F. and Clark, A. L. (2014) Is heart rate important for patients with heart failure in atrial fibrillation? JACC: Heart Failure, 2(3), pp. 213-220. (doi: 10.1016/j.jchf.2014.01.005) (PMID:24952686)

Goode, K. M., Nicholls, R., Pellicori, P., Clark, A. L. and Cleland, J. G.F. (2014) The in vitro stability of novel cardiovascular and sepsis biomarkers at ambient temperature. Clinical Chemistry and Laboratory Medicine, 52(6), pp. 911-918. (doi: 10.1515/cclm-2013-0767) (PMID:24406281)

Ingle, L., Cleland, J.G. and Clark, A.L. (2014) The relation between repeated 6-minute walk test performance and outcome in patients with chronic heart failure. Annals of Physical and Rehabilitation Medicine, 57(4), pp. 244-253. (doi: 10.1016/j.rehab.2014.03.004) (PMID:24835160)

Mentz, R. J. et al. (2014) International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. European Journal of Heart Failure, 16(6), pp. 614-624. (doi: 10.1002/ejhf.92) (PMID:24771609)

Rogers, J. K. et al. (2014) Effect of rosuvastatin on repeat heart failure hospitalizations: The CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC: Heart Failure, 2(3), pp. 289-297. (doi: 10.1016/j.jchf.2013.12.007)

Valente, M.A.E. et al. (2014) Diuretic response in acute heart failure: clinical characteristics and prognostic significance. European Heart Journal, 35(19), pp. 1284-1293. (doi: 10.1093/eurheartj/ehu065) (PMID:24585267)

Ingle, L., Rigby, A. S., Sloan, R., Carroll, S., Goode, K. M., Cleland, J. G. and Clark, A. L. (2014) Development of a composite model derived from cardiopulmonary exercise tests to predict mortality risk in patients with mild-to-moderate heart failure. Heart, 100(10), pp. 781-786. (doi: 10.1136/heartjnl-2013-304614) (PMID:24567314)

Mentz, R. J. et al. (2014) Decongestion in acute heart failure. European Journal of Heart Failure, 16(5), pp. 471-482. (doi: 10.1002/ejhf.74) (PMID:24599738) (PMCID:PMC4659502)

Cleland, J. G.F. and Parsons, S. (2014) Aspirin for heart failure: theory- or evidence-based? Circulation: Heart Failure, 7(2), pp. 237-238. (doi: 10.1161/CIRCHEARTFAILURE.114.001155) (PMID:24643886)

Poolsawad, N., Moore, L., Kambhampati, C. and Cleland, J. G.F. (2014) Issues in the mining of heart failure datasets. International Journal of Automation and Computing, 11(2), pp. 162-179. (doi: 10.1007/s11633-014-0778-5)

Perez-Moreno, A. C. et al. (2014) Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC: Heart Failure, 2(2), pp. 187-197. (doi: 10.1016/j.jchf.2014.01.001) (PMID:24720928)

Ingle, L., Cleland, J. G. and Clark, A. L. (2014) The long-term prognostic significance of 6-minute walk test distance in patients with chronic heart failure. BioMed Research International, 2014, 505969. (doi: 10.1155/2014/505969) (PMID:24800236) (PMCID:PMC3985138)

Gheorghiade, M. et al. (2014) Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Failure Reviews, 19(2), pp. 135-152. (doi: 10.1007/s10741-012-9361-8) (PMID:23099992) (PMCID:PMC4161017)

Perez, A. C., Jhund, P. S. , Stott, D. J. , Gullestad, L., Cleland, J. G.F. , van Veldhuisen, D. J., Wikstrand, J., Kjekshus, J. and McMurray, J. J.V. (2014) Thyroid-stimulating hormone and clinical outcomes. JACC: Heart Failure, 2(1), pp. 35-40. (doi: 10.1016/j.jchf.2013.07.008)

Cleland, J.G. et al. (2014) Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function (PROTECT) study. Circulation: Heart Failure, 7(1), pp. 76-87. (doi: 10.1161/CIRCHEARTFAILURE.113.000284) (PMID:24281134)

Givertz, M.M. et al. (2014) Renal function trajectories and clinical outcomes in acute heart failure. Circulation: Heart Failure, 7(1), pp. 59-67. (doi: 10.1161/CIRCHEARTFAILURE.113.000556) (PMID:24281137)

Dobre, D. et al. (2014) Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. European Journal of Heart Failure, 16(1), pp. 76-85. (doi: 10.1093/eurjhf/hft129) (PMID:23928650)

Bouri, S., Whinnett, Z. I., Cole, G. D., Manisty, C. H., Cleland, J. G.F. and Francis, D. P. (2014) Definitions of outcome, response and effect in imaging research to avoid confusion. JACC: Cardiovascular Imaging, 7(1), pp. 104-106. (doi: 10.1016/j.jcmg.2013.11.001) (PMID:24433715)

Pellicori, P., Kallvikbacka-Bennett, A., Zhang, J., Khaleva, O., Warden, J., Clark, A. L. and Cleland, J. G.F. (2014) Revisiting a classical clinical sign: Jugular venous ultrasound. International Journal of Cardiology, 170(3), pp. 364-370. (doi: 10.1016/j.ijcard.2013.11.015) (PMID:24315339)

Lewinter, C., Bland, J. M., Crouch, S., Cleland, J. G.F. , Doherty, P., LeWinter, M. M., Køber, L., Hall, A. S. and Gale, C. P. (2014) Impact of aspirin and statins on long-term survival in patients hospitalized with acute myocardial infarction complicated by heart failure: an analysis of 1706 patients. European Journal of Heart Failure, 16(1), pp. 95-102. (doi: 10.1002/ejhf.40) (PMID:24453098)

Pellicori, P., Kallvikbacka-Bennett, A., Khaleva, O., Carubelli, V., Costanzo, P., Castiello, T., Wong, K., Zhang, J., Cleland, J. G.F. and Clark, A. L. (2014) Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification? International Journal of Cardiovascular Imaging, 30(1), pp. 69-79. (doi: 10.1007/s10554-013-0310-y) (PMID:24150723)

Jacobs, L. et al. (2014) Heart 'omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database. Journal of Biomedical Research, 28(5), pp. 349-359. (doi: 10.7555/JBR.28.20140045) (PMID:25332706) (PMCID:PMC4197385)

2013

Brignole, M. et al. (2013) 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace, 15(8), pp. 1070-1118. (doi: 10.1093/europace/eut206)

Cleland, J. G. , Abraham, W. T., Linde, C., Gold, M. R., Young, J. B., Daubert, J. C., Sherfesee, L., Wells, G. A. and Tang, A. S.L. (2013) An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. European Heart Journal, 34(46), pp. 3547-3556. (doi: 10.1093/eurheartj/eht290) (PMID:23900696) (PMCID:PMC3855551)

2012

Ingle, L., Sloan, R., Carroll, S., Goode, K., Cleland, J. G. and Clark, A. L. (2012) Influence of body mass on risk prediction during cardiopulmonary exercise testing in patients with chronic heart failure. Experimental and Clinical Cardiology, 17(4), pp. 179-182. (PMID:23592931) (PMCID:PMC3627270)

Pepera, G. K., Sandercock, G. R., Sloan, R., Cleland, J. J.F. , Ingle, L. and Clark, A. L. (2012) Influence of step length on 6-minute walk test performance in patients with chronic heart failure. Physiotherapy, 98(4), pp. 325-329. (doi: 10.1016/j.physio.2011.08.005) (PMID:23122439)

Rho, R. W., Patton, K. K., Poole, J. E., Cleland, J. G. , Shadman, R., Anand, I., Maggioni, A. P., Carson, P. E., Swedberg, K. and Levy, W. C. (2012) Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator. Circulation, 126(20), pp. 2402-2407. (doi: 10.1161/CIRCULATIONAHA.111.069245) (PMID:23072904)

Buga, L. and Cleland, J. G.F. (2012) Increasing knowledge and changing views in cardiac resynchronization therapy. Heart Failure Reviews, 17(6), pp. 721-725. (doi: 10.1007/s10741-011-9281-z) (PMID:21932145)

Cleland, J. G.F. and Ghio, S. (2012) The determinants of clinical outcome and clinical response to CRT are not the same. Heart Failure Reviews, 17(6), pp. 755-766. (doi: 10.1007/s10741-011-9268-9) (PMID:22081054)

Pellicori, P., Sherwi, N., Khaleva, O., Wong, K. and Cleland, J. G.F. (2012) An atrial mass: the value of echocardiographic three-dimensional reconstruction. Journal of Cardiovascular Medicine, 13(11), pp. 769-770. (doi: 10.2459/JCM.0b013e32834917ed) (PMID:21709575)

Cleland, J. G.F. and Clark, A. L. (2012) Heart failure—does it matter whether LVEF is reduced? Lancet, 380(9851), pp. 1363-1365. (doi: 10.1016/S0140-6736(12)61349-X) (PMID:22932711)

Manzano, L., Escobar, C., Cleland, J. G.F. and Flather, M. (2012) Diagnosis of elderly patients with heart failure. European Journal of Heart Failure, 14(10), pp. 1097-1103. (doi: 10.1093/eurjhf/hfs109) (PMID:22771845)

Daubert, J.-C. et al. (2012) 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm, 9(9), pp. 1524-1576. (doi: 10.1016/j.hrthm.2012.07.025) (PMID:22939223)

Storrow, A. B. et al. (2012) Standardized reporting criteria for studies evaluating suspected acute heart failure syndromes in the emergency department. Journal of the American College of Cardiology, 60(9), pp. 822-832. (doi: 10.1016/j.jacc.2012.03.072) (PMID:22917006)

Kohan, D. E., Cleland, J. G. , Rubin, L. J., Theodorescu, D. and Barton, M. (2012) Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve? Life Sciences, 91(13-14), pp. 528-539. (doi: 10.1016/j.lfs.2012.07.034) (PMID:22967485)

Oxberry, S. G., Bland, J. M., Clark, A. L., Cleland, J. G.F. and Johnson, M. J. (2012) Minimally clinically important difference in chronic breathlessness: Every little helps. American Heart Journal, 164(2), pp. 229-235. (doi: 10.1016/j.ahj.2012.05.003) (PMID:22877809)

Poolsawad, N., Moore, L., Kambhampati, C. and Cleland, J.G.F. (2012) Handling Missing Values in Data Mining - A Case Study of Heart Failure Dataset. In: 9th International Conference on Fuzzy Systems and Knowledge Discovery (FSKD), Sichuan, China, 29-31 May 2012, pp. 2934-2938. ISBN 9781467300254 (doi: 10.1109/FSKD.2012.6233860)

Bourantas, C. V. et al. (2012) Renal artery stenosis: an innocent bystander or an independent predictor of worse outcome in patients with chronic heart failure? A magnetic resonance imaging study. European Journal of Heart Failure, 14(7), pp. 764-772. (doi: 10.1093/eurjhf/hfs057) (PMID:22508558)

Cullington, D., Goode, K. M., Clark, A. L. and Cleland, J. G.F. (2012) Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? European Journal of Heart Failure, 14(7), pp. 737-747. (doi: 10.1093/eurjhf/hfs060) (PMID:22622001)

Ingle, L., Hobkirk, J., Damy, T., Nabb, S., Clark, A. L. and Cleland, J. G.F. (2012) Experiences of air travel in patients with chronic heart failure. International Journal of Cardiology, 158(1), pp. 66-70. (doi: 10.1016/j.ijcard.2010.12.101) (PMID:21256607) (PMCID:PMC3387374)

Cleland, J. G.F. , Freemantle, N., Erdmann, E., Gras, D., Kappenberger, L., Tavazzi, L. and Daubert, J.-C. (2012) Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial. European Journal of Heart Failure, 14(6), pp. 628-634. (doi: 10.1093/eurjhf/hfs055) (PMID:22552183)

Cleland, J. G.F. , Mumtaz, S. and Cecchini, L. (2012) Role of antithrombotic agents in heart failure. Current Cardiology Reports, 14(3), pp. 314-325. (doi: 10.1007/s11886-012-0266-x) (PMID:22467260)

O'Connor, C. M. et al. (2012) The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. European Journal of Heart Failure, 14(6), pp. 605-612. (doi: 10.1093/eurjhf/hfs029) (PMID:22535795)

Ingle, L., Cleland, J. G. and Clark, A. L. (2012) Body mass index is related to the perception of exertional breathlessness in patients presenting with dyspnoea of unknown origin. International Journal of Cardiology, 157(2), pp. 300-303. (doi: 10.1016/j.ijcard.2012.03.113) (PMID:22483253)

Cleland, J. G.F. , Taylor, J., Freemantle, N., Goode, K. M., Rigby, A. S. and Tendera, M. (2012) Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure, 14(5), pp. 487-494. (doi: 10.1093/eurjhf/hfs049) (PMID:22505395)

Cleland, J. G.F. (2012) Does aspirin really reduce the risk of colon cancer? Lancet, 379(9826), p. 1586. (doi: 10.1016/S0140-6736(12)60671-0) (PMID:22541575)

Bourantas, C. V. et al. (2012) Atherosclerotic disease of the abdominal aorta and its branches: prognostic implications in patients with heart failure. Heart Failure Reviews, 17(2), pp. 229-239. (doi: 10.1007/s10741-011-9284-9) (PMID:22002211)

Broch, K. et al. (2012) Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. European Journal of Heart Failure, 14(3), pp. 268-277. (doi: 10.1093/eurjhf/hfs006) (PMID:22302661)

Cleland, J. G.F. , Carubelli, V., Castiello, T., Yassin, A., Pellicori, P. and Antony, R. (2012) Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Failure Reviews, 17(2), pp. 133-149. (doi: 10.1007/s10741-012-9306-2) (PMID:22426973)

Damy, T. et al. (2012) Prevalence of, associations with, and prognostic value of Tricuspid Annular Plane Systolic Excursion (TAPSE) among out-patients referred for the evaluation of heart failure. Journal of Cardiac Failure, 18(3), pp. 216-225. (doi: 10.1016/j.cardfail.2011.12.003) (PMID:22385942)

Teerlink, J. R. et al. (2012) The safety of an adenosine A1-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: Findings from PROTECT. Drug Safety, 35(3), pp. 233-244. (doi: 10.2165/11594680-000000000-00000) (PMID:22339573)

Ardehali, H. et al. (2012) Targeting myocardial substrate metabolism in heart failure: potential for new therapies. European Journal of Heart Failure, 14(2), pp. 120-129. (doi: 10.1093/eurjhf/hfr173) (PMID:22253453) (PMCID:PMC3260022)

Cleland, J. G.F. (2012) Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular disease. American Journal of Medicine, 125(2), e13. (doi: 10.1016/j.amjmed.2011.08.027) (PMID:22269629)

Costanzo, P., Cleland, J.G. , Atkin, S. L., Vassallo, E. and Perrone-Filardi, P. (2012) Use of carotid intima-media thickness regression to guide therapy and management of cardiac risks. Current Treatment Options in Cardiovascular Medicine, 14(1), pp. 50-56. (doi: 10.1007/s11936-011-0158-1) (PMID:22139639)

Rossignol, P., Cleland, J. G.F. , Bhandari, S., Tala, S., Gustafsson, F., Fay, R., Lamiral, Z., Dobre, D., Pitt, B. and Zannad, F. (2012) Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation, 125(2), pp. 271-279. (doi: 10.1161/CIRCULATIONAHA.111.028282) (PMID:22128223)

Bogale, N. et al. (2012) The European CRT Survey: 1 year (9-15 months) follow-up results. European Journal of Heart Failure, 14(1), pp. 61-73. (doi: 10.1093/eurjhf/hfr158) (PMID:22179034)

Lopez-Andrès, N., Rossignol, P., Iraqi, W., Fay, R., Nuée, J., Ghio, S., Cleland, J. G.F. , Zannad, F. and Lacolley, P. (2012) Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. European Journal of Heart Failure, 14(1), pp. 74-81. (doi: 10.1093/eurjhf/hfr151) (PMID:22089058)

Gullestad, L. et al. (2012) Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal, 33(18), pp. 2290-2296. (doi: 10.1093/eurheartj/ehs077) (PMID:22513778)

Ingle, L., Sloan, R., Carroll, S., Goode, K., Cleland, J. G. and Clark, A. L. (2012) Abnormalities of the ventilatory equivalent for carbon dioxide in patients with chronic heart failure. Pulmonary Medicine, 2012, 589164. (doi: 10.1155/2012/589164) (PMID:22619715) (PMCID:PMC3350981)

Zannad, F. et al. (2012) Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements? European Heart Journal, 33(9), pp. 1049-1057. (doi: 10.1093/eurheartj/ehr437) (PMID:22422830)

2011

Cleland, J. G.F. , Coletta, A. P., Cullington, D., Castiello, T., de Boer, R. A. and Clark, A. L. (2011) Clinical trials update from the European Society of Cardiology Meeting 2011: ARISTOTLE, SMART-AV: QLV substudy, SHIFT: echocardiography and quality of life substudies, European CRT Survey, and Basic Science Update. European Journal of Heart Failure, 13(12), pp. 1376-1380. (doi: 10.1093/eurjhf/hfr149) (PMID:22102626)

Damy, T. et al. (2011) Does the physical examination still have a role in patients with suspected heart failure? European Journal of Heart Failure, 13(12), pp. 1340-1348. (doi: 10.1093/eurjhf/hfr128) (PMID:21990340)

Lewinter, C., Torp-Pedersen, C., Cleland, J. G.F. and Køber, L. (2011) Right and left bundle branch block as predictors of long-term mortality following myocardial infarction. European Journal of Heart Failure, 13(12), pp. 1349-1354. (doi: 10.1093/eurjhf/hfr130) (PMID:22027083)

O'Connor, C. M. et al. (2011) Impact of serial troponin release on outcomes in patients with acute heart failure: Analysis from the PROTECT pilot study. Circulation: Heart Failure, 4(6), pp. 724-732. (doi: 10.1161/CIRCHEARTFAILURE.111.961581) (PMID:21900185)

Ariti, C. A., Cleland, J. G.F. , Pocock, S. J., Pfeffer, M. A., Swedberg, K., Granger, C. B., McMurray, J. J.V. , Michelson, E. L., Östergren, J. and Yusuf, S. (2011) Days alive and out of hospital and the patient journey in patients with heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal, 162(5), pp. 900-906. (doi: 10.1016/j.ahj.2011.08.003) (PMID:22093207)

Harinstein, M. E. et al. (2011) Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period. Heart, 97(19), pp. 1607-1618. (doi: 10.1136/hrt.2011.222331) (PMID:21900586)

Cleland, J. G.F. , Coletta, A. P., Castiello, T. and Clark, A. L. (2011) Clinical trials update from the European Society of Cardiology Heart Failure meeting 2011: TEHAF, WHICH, CARVIVA, and atrial fibrillation in GISSI-HF and EMPHASIS-HF. European Journal of Heart Failure, 13(10), pp. 1147-1151. (doi: 10.1093/eurjhf/hfr119) (PMID:21896537)

Anand, I. S. et al. (2011) Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation: Heart Failure, 4(5), pp. 569-577. (doi: 10.1161/CIRCHEARTFAILURE.111.962654) (PMID:21715583)

Costanzo, P., Cleland, J. G. , Vassallo, E. and Perrone-Filardi, P. (2011) Questioning the predictive role of carotid intima–media thickness. Future Cardiology, 7(5), pp. 651-656. (doi: 10.2217/fca.11.44) (PMID:21929345)

Cleland, J. G.F. and Antony, R. (2011) It makes SENSE to take a safer road. European Heart Journal, 32(18), pp. 2225-2227. (doi: 10.1093/eurheartj/ehr120) (PMID:21551157)

Inglis, S. C., Clark, R. A., McAlister, F. A., Stewart, S. and Cleland, J. G.F. (2011) Which components of heart failure programmes are effective? A systematic review and meta-analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: Abridged Cochrane Review. European Journal of Heart Failure, 13(9), pp. 1028-1040. (doi: 10.1093/eurjhf/hfr039) (PMID:21733889)

Oxberry, S. G., Torgerson, D. J., Bland, J. M., Clark, A. L., Cleland, J. G.F. and Johnson, M. J. (2011) Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure, 13(9), pp. 1006-1012. (doi: 10.1093/eurjhf/hfr068) (PMID:21712288)

Cleland, J. G.F. et al. (2011) The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet, 378(9792), pp. 676-683. (doi: 10.1016/S0140-6736(11)61126-4) (PMID:21856481)

Cleland, J. G.F. , McDonagh, T. and Dargie, H. J. (2011) The authors' reply. Heart, 97(14), p. 1191. (doi: 10.1136/heartjnl-2011-300372)

Cleland, J. G.F. and Freemantle, N. (2011) Revascularization for patients with heart failure. Inconsistencies between theory and practice. European Journal of Heart Failure, 13(7), pp. 694-697. (doi: 10.1093/eurjhf/hfr075) (PMID:21712291)

Metra, M. et al. (2011) Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. European Heart Journal, 32(12), pp. 1519-1534. (doi: 10.1093/eurheartj/ehr042) (PMID:21388992)

Voors, A. A. et al. (2011) Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). Journal of the American College of Cardiology, 57(19), pp. 1899-1907. (doi: 10.1016/j.jacc.2010.11.057) (PMID:21545947)

Ingle, L., Sloan, R., Carroll, S., Goode, K., Cleland, J. G. and Clark, A. L. (2011) Prognostic significance of different measures of the ventilation-carbon dioxide relation in patients with suspected heart failure. European Journal of Heart Failure, 13(5), pp. 537-542. (doi: 10.1093/eurjhf/hfq238) (PMID:21247919)

Villard, E. et al. (2011) A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. European Heart Journal, 32(9), pp. 1065-1076. (doi: 10.1093/eurheartj/ehr105) (PMID:21459883) (PMCID:PMC3086901)

Cleland, J. G.F. , Coletta, A. P., Buga, L., Antony, R., Pellicori, P., Freemantle, N. and Clark, A. L. (2011) Clinical trials update from the American Heart Association Meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT. European Journal of Heart Failure, 13(4), pp. 460-465. (doi: 10.1093/eurjhf/hfr015) (PMID:21436363)

Inglis, S. C., Clark, R. A. and Cleland, J. G.F. (2011) Telemonitoring in patients with heart failure [2]. New England Journal of Medicine, 364(11), pp. 1078-1080. (doi: 10.1056/NEJMc1100395) (PMID:21410377)

Shelton, R. J., Brown, B. D., Allinson, A., Johnson, T., Smales, C., Jolly, S. and Cleland, J. G.F. (2011) A comparison between monophasic and biphasic defibrillation for the cardioversion of persistent atrial fibrillation in patients with and without heart failure. International Journal of Cardiology, 147(3), pp. 405-408. (doi: 10.1016/j.ijcard.2009.09.545) (PMID:19861229)

Cleland, J. G.F. , Calvert, M., Freemantle, N., Arrow, Y., Ball, S. G., Bonser, R. S., Chattopadhyay, S., Norell, M. S., Pennell, D. J. and Senior, R. (2011) The Heart Failure Revascularisation Trial (HEART). European Journal of Heart Failure, 13(2), pp. 227-233. (doi: 10.1093/eurjhf/hfq230) (PMID:21156659)

Frankenstein, L., Goode, K., Ingle, L., Remppis, A., Schellberg, D., Nelles, M., Katus, H.A., Clark, A.L., Cleland, J.G.F. and Zugck, C. (2011) Derivation and validation of a simple clinical risk-model in heart failure based on 6 minute walk test performance and NT-proBNP status – Do we need specificity for sex and beta-blockers? International Journal of Cardiology, 147(1), pp. 74-78. (doi: 10.1016/j.ijcard.2009.08.005) (PMID:19765836)

Bourantas, C. V. et al. (2011) Relationship between right ventricular volumes measured by cardiac magnetic resonance imaging and prognosis in patients with chronic heart failure. European Journal of Heart Failure, 13(1), pp. 52-60. (doi: 10.1093/eurjhf/hfq161) (PMID:20930000)

Bogale, N., Witte, K., Priori, S., Cleland, J. , Auricchio, A., Gadler, F., Gitt, A., Limbourg, T., Linde, C. and Dickstein, K. (2011) The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. European Journal of Heart Failure, 13(9), pp. 974-983. (doi: 10.1093/eurjhf/hfr085) (PMID:21771823)

Bourantas, C. V. et al. (2011) Prevalence of scarred and dysfunctional myocardium in patients with heart failure of ischaemic origin: A cardiovascular magnetic resonance study. Journal of Cardiovascular Magnetic Resonance, 13(1), 53. (doi: 10.1186/1532-429X-13-53) (PMID:21936915) (PMCID:PMC3190338)

Cleland, J. G.F. , Coletta, A. P., Freemantle, N. and Clark, A. L. (2011) Clinical trials update from the American College of Cardiology Meeting 2011: STICH, NorthStar, TARGET, and EVEREST II. European Journal of Heart Failure, 13(7), pp. 805-808. (doi: 10.1093/eurjhf/hfr077) (PMID:21712293)

Cleland, J. G.F. , McDonagh, T., Rigby, A. S., Yassin, A., Whittaker, T. and Dargie, H. J. (2011) The national heart failure audit for England and Wales 2008-2009. Heart, 97(11), pp. 876-886. (doi: 10.1136/hrt.2010.209171) (PMID:21173198)

Cullington, D., Esmail, S., Hurren, S., Cleland, J.G.F. , Clark, A. L. and Alamgir, M. F. (2011) Unmasking the truth. BMJ Case Reports, 2011, bcr0720103. (doi: 10.1136/bcr.07.2010.3193)

Cullington, D., Goode, K. M., Cleland, J. G.F. and Clark, A. L. (2011) Limited role for ivabradine in the treatment of chronic heart failure. Heart, 97(23), pp. 1961-1966. (doi: 10.1136/heartjnl-2011-300041) (PMID:21917660)

Futter, J. E., Cleland, J. G.F. and Clark, A. L. (2011) Body mass indices and outcome in patients with chronic heart failure. European Journal of Heart Failure, 13(2), pp. 207-213. (doi: 10.1093/eurjhf/hfq218) (PMID:21138908)

2010

Massie, B. M. et al. (2010) Rolofylline, an adenosine A1−receptor antagonist, in acute heart failure. New England Journal of Medicine, 363(15), pp. 1419-1428. (doi: 10.1056/NEJMoa0912613) (PMID:20925544)

2009

Cleland, J. et al. (2009) Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin A Report From CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). Journal of the American College of Cardiology, 54(20), pp. 1850-1859. (doi: 10.1016/j.jacc.2009.06.041)

2008

Coletta, A. P., Cullington, D., Clark, A. L. and Cleland, J. G.F. (2008) Clinical trials update from European Society of Cardiology meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF, and HOME-HF. European Journal of Heart Failure, 10(12), pp. 1264-1267. (doi: 10.1016/j.ejheart.2008.10.002) (PMID:19008149)

Coletta, A. P., Cleland, J. G.F. , Cullington, D. and Clark, A. L. (2008) Clinical trials update from heart rhythm 2008 and heart failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452. European Journal of Heart Failure, 10(9), pp. 917-920. (doi: 10.1016/j.ejheart.2008.07.006) (PMID:18678526)

Cleland, J. G.F. , Coletta, A. P., Yassin, A., Hado, H., Cullington, D., Abdellah, A. T. and Clark, A. L. (2008) Clinical trials update from the American College of Cardiology 2008: carisma, trends, meta-analysis of cox-2 studies, hat, on-target, hyvet, accomplish, momentum, protect, horizon-hf and reverse. European Journal of Heart Failure, 10(6), pp. 614-620. (doi: 10.1016/j.ejheart.2008.05.003) (PMID:18502685)

Goode, K. M., Nabb, S., Cleland, J. G.F. and Clark, A. L. (2008) A comparison of patient and physician-rated New York Heart Association class in a community-based heart failure clinic. Journal of Cardiac Failure, 14(5), pp. 379-387. (doi: 10.1016/j.cardfail.2008.01.014) (PMID:18514929)

Pang, P. S. et al. (2008) A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. European Heart Journal, 29(6), pp. 816-824. (doi: 10.1093/eurheartj/ehn048) (PMID:18310669)

Cleland, J. G.F. , Coletta, A. P., Abdellah, A. T., Cullington, D., Clark, A. L. and Rigby, A. S. (2008) Clinical trials update from the American Heart Association 2007: CORONA, Rethin0, MASCOT, AF-CHF, HART, MASTER, POISE and stem cell therapy. European Journal of Heart Failure, 10(1), pp. 102-108. (doi: 10.1016/j.ejheart.2007.12.004) (PMID:18179987)

Cleland, J. G.F. (2008) Classification of the level of evidence in international guidelines for acute and chronic heart failure. Acute Heart Failure, pp. 885-891. (doi: 10.1007/978-1-84628-782-4_82)

Cleland, J. G.F. (2008) The epidemiology of heart failure. In: Beattie, J. and Goodlin, S. (eds.) Supportive Care in Heart Failure. Oxford University Press: Oxford, pp. 9-26. ISBN 9780198570288 (doi: 10.1093/acprof:oso/9780198570288.003.0002)

2005

Cleland, J. G.F. , Daubert, J.-C., Erdmann, E., Freemantle, N., Gras, D., Kappenberger, L. and Tavazzi, L. (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. New England Journal of Medicine, 352(15), pp. 1539-1549. (doi: 10.1056/NEJMoa050496) (PMID:15753115)

2003

Cleland, J.G.F. , Pennell, D.J., Ray, S.G., Coats, A.J., Macfarlane, P.W., Murray, G.D., Mule, J.D., Vered, Z. and Lahiri, A. (2003) Myocardial viability as a determinant of the ejection fraction response to Carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet, 362(9377), pp. 14-21. (doi: 10.1016/S0140-6736(03)13801-9) (PMID:12853194)

Poole-Wilson, P. A. et al. (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 362(9377), pp. 7-13. (doi: 10.1016/S0140-6736(03)13800-7) (PMID:12853193)

2002

Cleland, J. G.F. et al. (2002) Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet, 360(9346), pp. 1631-1639. (doi: 10.1016/S0140-6736(02)11601-1) (PMID:12457785)

Follath, F. et al. (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet, 360(9328), pp. 196-202. (doi: 10.1016/S0140-6736(02)09455-2) (PMID:12133653)